<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Azithromycin (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Azithromycin (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Azithromycin (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8868" href="/d/html/8868.html" rel="external">see "Azithromycin (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="10968" href="/d/html/10968.html" rel="external">see "Azithromycin (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F7983183"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Zithromax;</li>
<li>Zithromax Tri-Pak;</li>
<li>Zithromax Z-Pak</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869061"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AG-Azithromycin;</li>
<li>APO-Azithromycin Z;</li>
<li>AURO-Azithromycin;</li>
<li>DOM-Azithromycin;</li>
<li>GEN-Azithromycin;</li>
<li>JAMP-Azithromycin;</li>
<li>M-Azithromycin;</li>
<li>Mar-Azithromycin;</li>
<li>NRA-Azithromycin;</li>
<li>PMS-Azithromycin;</li>
<li>PRO-Azithromycin;</li>
<li>RATIO-Azithromycin;</li>
<li>RIVA-Azithromycin;</li>
<li>SANDOZ Azithromycin;</li>
<li>TEVA-Azithromycin;</li>
<li>Zithromax</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10585820"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Macrolide</span></li></ul></div>
<div class="block don drugH1Div" id="F53462651"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> With oral therapy, monitor for infantile hypertrophic pyloric stenosis (IHPS).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Limited data available: Preterm and term neonates: Oral, IV: 10 mg/kg/dose once daily; higher doses may be needed for some indications; see indication-specific dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="26f99306-29c6-4a27-86ec-81419c4326de">
<i>Chlamydia trachomatis</i> congenital infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Chlamydia trachomatis</i> congenital infection (conjunctivitis or pneumonia), treatment (alternative):</b> Limited data available: Preterm and term neonates: Oral: 20 mg/kg/dose once daily for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-9849993','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-9849993','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f573e1c-a236-4e93-a9e3-ccd522d76fbf">Pertussis, treatment or postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pertussis, treatment or postexposure prophylaxis:</b> Limited data available: Preterm and term neonates: Oral, IV: 10 mg/kg/dose once daily for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-16340941','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-16340941','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1dfb9fda-42c9-403c-b14c-17dc819aa589">
<i>Ureaplasma</i> spp., respiratory eradication in extremely low gestation newborns</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Ureaplasma</b></i>
<b> spp.,</b>
<b>respiratory eradication in extremely low gestation newborns: </b>Limited data available: GA 24 to &lt;29 weeks, PNA &lt;72 hours: IV: 20 mg/kg/dose every 24 hours for 3 doses. Dosing based on a prospective, multicenter study of preterm neonates randomized to receive azithromycin or placebo (total n=121; azithromycin group n=60); all patients were cultured for <i>Ureaplasma</i> prior to the first dose of study drug. <i>Ureaplasma</i>-positive patients (total n=44; azithromycin group n=19) receiving azithromycin had successful elimination following treatment and had a significantly higher rate of <i>Ureaplasma</i>-free survival, defined as survival to NICU discharge with 3 negative cultures post-treatment, compared to <i>Ureaplasma</i>-positive patients receiving placebo (84% vs 12%). Bronchopulmonary dysplasia occurred less in the <i>Ureaplasma-</i>positive azithromycin group vs placebo (38% vs 75%), but the difference was not statistically significant. At 2-year follow-up, overall survival and pulmonary and neurodevelopmental outcomes were similar between treatment groups; however, <i>Ureaplasma</i>-positive patients receiving azithromycin experienced more serious respiratory morbidity than patients in the placebo group (45% vs 15%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25385115','lexi-content-ref-32170033','lexi-content-ref-33658655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25385115','lexi-content-ref-32170033','lexi-content-ref-33658655'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F7983293"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 5 to 12 mg/kg/dose; typically administered as 10 to 12 mg/kg/dose on day 1 (usual maximum dose: 500 mg/dose) followed by 5 to 6 mg/kg once daily (usual maximum dose: 250 mg/dose) for remainder of treatment duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 10 mg/kg once daily; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2c04f789-5b51-49cc-b68d-d3d58ad6925e">Babesiosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Babesiosis:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mild to moderate disease: </i>Oral: 10 mg/kg once on day 1 (maximum dose: 500 mg/dose), then 5 mg/kg/dose once daily (maximum dose: 250 mg/dose) in combination with atovaquone; in immunocompromised patients, higher doses (eg, adolescents: 500 to 1,000 mg daily) have been used. Typically treat for a total duration of 7 to 10 days; longer duration may be necessary in some patients with severe or persistent symptoms until parasitemia is cleared (eg, ≥6 weeks with ≥2 weeks of negative blood smears in severely immunocompromised patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17029130','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17029130','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Severe disease</i>
<i>: </i>IV: 10 mg/kg/dose once daily; maximum dose: 500 mg. In immunocompromised patients, higher doses (eg, adolescents: 500 to 1,000 mg daily) have been used. Transition to oral azithromycin therapy once symptoms abate for a total duration of 7 to 10 days; longer duration may be necessary in some patients with severe or persistent symptoms until parasitemia is cleared (eg, ≥6 weeks with ≥2 weeks of negative blood smears in severely immunocompromised patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3dfaf432-6a64-4026-b536-99c2a9c13752">Cat scratch disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cat scratch disease (<i>Bartonella henselae)</i> (lymphadenitis)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>): Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents weighing ≤45 kg: Oral: 10 mg/kg once on day 1 (maximum dose: 500 mg/dose), then 5 mg/kg/dose once daily for 4 additional days (maximum dose: 250 mg/dose).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents weighing &gt;45 kg: Oral: 500 mg as a single dose on day 1, then 250 mg once daily for 4 additional days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6e2a56fe-ae38-44c3-9cbe-f0cf191e8b37">Chancroid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chancroid <i>(Haemophilus ducreyi): </i></b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;45 kg: Oral: 20 mg/kg as a single dose; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥45 kg and Adolescents: Oral: 1,000 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f392581d-56e1-49fb-b3b8-a966080e7091">
<i>Chlamydia trachomatis</i> infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Chlamydia trachomatis</i> infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urogenital/anogenital tract or oropharyngeal infection (eg, cervicitis [including presumptive treatment], urethritis)</i>: Children &lt;8 years weighing ≥45 kg <b>or</b> Children ≥8 years and Adolescents: Oral: 1,000 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.1'])">Ref</a></span>). For presumptive treatment of cervicitis, if the patient is at risk for gonorrhea or lives in a community where gonorrhea prevalence is high, consider also treating for gonococcal infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pneumonia, congenital</i>: Infants: Oral, IV: 20 mg/kg/dose once daily for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7130fea1-030c-4496-822e-505264056ed4">Cholera, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cholera (<i>Vibrio cholerae)</i>, treatment:</b> Limited data available: Infants, Children, and Adolescents: Oral: 20 mg/kg as a single dose in combination with hydration; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-GTFCC.1','lexi-content-ref-19578229','lexi-content-ref-12480424','lexi-content-ref-AAP.1','lexi-content-ref-29790845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-GTFCC.1','lexi-content-ref-19578229','lexi-content-ref-12480424','lexi-content-ref-AAP.1','lexi-content-ref-29790845'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0b6279a1-a24a-4972-af37-a8df1ea98337">Cystic fibrosis; chronic lung maintenance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis; chronic lung maintenance:</b> Limited data available; dosing regimen variable: <b>Note</b>: Recommended for use in patients with a history of <i>Pseudomonas aeruginosa; </i>may also be considered in patients without <i>Pseudomonas</i> who experience frequent exacerbations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23540878','lexi-content-ref-31661302','lexi-content-ref-14519709','lexi-content-ref-20442386','lexi-content-ref-22684984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23540878','lexi-content-ref-31661302','lexi-content-ref-14519709','lexi-content-ref-20442386','lexi-content-ref-22684984'])">Ref</a></span>). Patients should be screened for nontuberculous mycobacterial infection prior to treatment (if able) and azithromycin should not be used if present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23540878','lexi-content-ref-14519709']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23540878','lexi-content-ref-14519709'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months, Children, and Adolescents: Oral: 10 mg/kg/dose 3 times weekly; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29890086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29890086'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed dosing:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14519709','lexi-content-ref-20442386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14519709','lexi-content-ref-20442386'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">18 to &lt;36 kg: Oral: 250 mg 3 times weekly (Monday, Wednesday, Friday).</p>
<p style="text-indent:-2em;margin-left:8em;">≥36 kg: Oral: 500 mg 3 times weekly (Monday, Wednesday, Friday).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5d023e55-125d-4860-afd8-9934c605a1da">Diarrhea, infectious</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diarrhea, infectious:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Campylobacter infection</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Oral: 10 mg/kg/dose once daily for 3 days; patients with HIV should receive treatment for 5 days; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4','lexi-content-ref-AAP.1','lexi-content-ref-28521004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4','lexi-content-ref-AAP.1','lexi-content-ref-28521004'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Shigellosis</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Patients without HIV: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">5-day regimen: Oral: 12 mg/kg once on day 1 (maximum dose: 500 mg/dose), followed by 5 mg/kg/dose once daily on days 2 to 5 (maximum dose: 250 mg/dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12712971']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12712971'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">3-day regimen: Oral: 10 mg/kg/dose once daily for 3 days; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19828533','lexi-content-ref-16267717']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19828533','lexi-content-ref-16267717'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients with HIV: Adolescents: Oral: 500 mg once daily for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d6b46673-8570-4914-ad98-b96bd4dd105b">Endocarditis, prophylaxis before invasive dental procedures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, prophylaxis before invasive dental procedures (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Alternative agent for use in patients with penicillin or ampicillin allergy. Recommended only in patients who are at highest risk for infective endocarditis (IE) or adverse outcomes (eg, history of IE, cardiac valve repair using prosthetic valves or material, unrepaired cyanotic congenital heart disease [CHD], left ventricular assist device or implantable heart, repaired CHD with prosthetic material or device during first 6 months after procedure, pulmonary artery valve or conduit placement [eg, Melody valve, Contegra conduit], repaired CHD with residual defects at the site or adjacent to site of prosthetic patch or device, heart transplant recipients with cardiac valvulopathy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317','lexi-content-ref-33853363','lexi-content-ref-28315732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317','lexi-content-ref-33853363','lexi-content-ref-28315732'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 15 mg/kg as a single dose administered 30 to 60 minutes before dental procedure; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33853363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33853363'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="94275df2-6a9f-438b-8861-72052261fd09">Gonococcal infection, uncomplicated infections of the cervix, urethra, or rectum</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gonococcal infection, uncomplicated infections of the cervix, urethra, or rectum (alternative agent):</b> Limited data available: <b>Note:</b> Only for use if ceftriaxone is not available or not feasible.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;45 kg and Adolescents: Oral: 2,000 mg as a single dose in combination with IM gentamicin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>). <b>Note:</b> For treatment failure, consult an infectious diseases specialist and report to the CDC through state and local health departments within 24 hours of diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e096d904-52ea-4eb0-a6d7-1e796cc45b21">Lyme disease, erythema migrans</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lyme disease (<i>Borrelia</i> spp. infection), erythema migrans (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 10 mg/kg/dose once daily for 7 days; maximum dose: 500 mg/dose. <b>Note:</b> Due to lower efficacy, should only be used when first-line agents cannot be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f432b107-cae5-4837-8cf7-e78dcd6458d0">Meningococcal disease, chemoprophylaxis for high-risk contacts</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningococcal disease, chemoprophylaxis for high-risk contacts (alternative agent):</b> Infants, Children, and Adolescents: Oral: 10 mg/kg as a single dose; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ab4a56e4-32ec-4776-b503-ce1b14d69f67">
<i>Mycobacterium avium</i> complex infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Mycobacterium avium</b></i>
<b> complex (MAC) infection (HIV-exposed/-infected):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Primary prophylaxis (patients who meet age-specific CD4 count thresholds): Oral: 20 mg/kg once <b>weekly</b> (maximum dose: 1,200 mg/dose) (preferred regimen) <b>or </b>alternatively, 5 mg/kg/dose once daily (maximum dose: 250 mg/dose); may be discontinued in children ≥2 years of age receiving stable antiretroviral therapy (ART) for ≥6 months and experiencing sustained (&gt;3 months) CD4 count recovery well above age-specific targets.</p>
<p style="text-indent:-2em;margin-left:6em;">Treatment (alternative to clarithromycin): Oral: 10 to 12 mg/kg/dose once daily as part of an appropriate combination regimen; maximum dose: 500 mg/dose; continue therapy for at least 12 months; following completion of treatment, initiate long-term suppression (secondary prophylaxis).</p>
<p style="text-indent:-2em;margin-left:6em;">Long-term suppression (secondary prophylaxis) (alternative to clarithromycin): Oral: 5 mg/kg/dose once daily as part of an appropriate combination regimen; consideration can be given to discontinuation of therapy in children ≥2 years when patient has completed ≥12 months of therapy, has no signs/symptoms of MAC disease, and has sustained (≥6 months) CD4 count recovery meeting age-specific thresholds in response to stable ART.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Primary prophylaxis (patients with CD4 count &lt;50 cells/mm<sup>3</sup> who are not initiated on fully suppressive ART): Oral: 1,200 mg once weekly (preferred) <b>or</b> 600 mg twice weekly; may discontinue prophylaxis when patient is initiated on effective ART.</p>
<p style="text-indent:-2em;margin-left:6em;">Treatment and long-term suppression (secondary prophylaxis): Oral: 500 to 600 mg daily as part of an appropriate combination regimen; may discontinue when patient has completed ≥12 months of therapy, has no signs or symptoms of MAC disease, and has sustained (≥6 months) CD4 count &gt;100 cells/mm<sup>3</sup> in response to ART.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a96b8104-65d0-48ba-b460-4308464e6db6">Otitis media, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute (AOM) (alternative agent for patients who cannot tolerate beta-lactam antibiotics):</b>
<b>Note:</b> Not recommended for routine empiric use due to limited efficacy against <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439909'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Single-dose regimen: Oral: 30 mg/kg once as a single dose; maximum dose: 1,500 mg/dose; if patient vomits within 30 minutes of dose, repeat dosing has been administered, although limited safety data are available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Three-day regimen: Oral: 10 mg/kg/dose once daily for 3 days; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> For recurrent or persistent infections, doses of 20 mg/kg/dose once daily for 3 days have been described in patients ≥6 months to &lt;6 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14506028']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14506028'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Five-day regimen: Oral: 10 mg/kg once on day 1 (maximum dose: 500 mg/dose), followed by 5 mg/kg/dose (maximum dose: 250 mg/dose) once daily on days 2 to 5 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ab8f1b30-cec2-4012-b46b-cfc140485c7c">Peritonitis, prophylaxis for patients receiving peritoneal dialysis who require dental procedures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis (peritoneal dialysis), prophylaxis for patients receiving peritoneal dialysis who require dental procedures:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 15 mg/kg administered 30 to 60 minutes before dental procedure; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c43d016-c199-4561-bd12-4713812696da">Pertussis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pertussis </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16340941','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16340941','lexi-content-ref-AAP.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 1 to &lt;6 months: Oral, IV: 10 mg/kg/dose once daily for 5 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months, Children, and Adolescents: Oral, IV: 10 mg/kg once on day 1 (maximum dose: 500 mg/dose), followed by 5 mg/kg/dose once daily on days 2 to 5 (maximum dose: 250 mg/dose).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed599b2f-52de-47cd-b7d2-d706008b1db0">Pneumonia, community-acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired (presumed atypical pneumonia or proven </b>
<i>
<b>C. pneumoniae </b></i>
<b>or </b>
<i>
<b>M. pneumoniae</b></i>
<b> infection) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587'])">Ref</a></span>): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild infection or step-down therapy: Infants &gt;3 months, Children, and Adolescents: Oral: 10 mg/kg once on day 1 (maximum dose: 500 mg/dose), followed by 5 mg/kg/dose (maximum dose: 250 mg/dose) once daily on days 2 to 5 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Severe infection: Infants &gt;3 months, Children, and Adolescents: IV: 10 mg/kg/dose once daily for at least 2 days (maximum dose: 500 mg/dose); when able transition to the oral route with a single daily dose of 5 mg/kg/dose (maximum dose: 250 mg/dose) to complete a 5-day course of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="84bd95cf-599b-41d5-88f3-4de27dcd958f">Recurrent asthma-like symptoms, reduction in duration</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Recurrent asthma-like symptoms, reduction in duration:</b> Limited data available: Children ≤3 years: Oral: 10 mg/kg/dose once daily for 3 days; dosing based on a randomized placebo-controlled trial (n=72; episodes of recurrent asthma-like symptoms analyzed=148; mean age: 2 ± 0.6 years); patients were diagnosed with recurrent troublesome lung symptoms (asthma-like episodes) and included in the study if they had ≥5 episodes in 6 months, persistent symptoms for ≥4 weeks, or previously experienced a severe acute episode requiring an oral steroid or hospital admission; patients presenting with ≥3 days of consecutive symptoms were randomized to azithromycin or placebo. Patients received a beta-2 agonist, with the potential to receive inhaled corticosteroids (82%), montelukast (60%), and/or oral prednisolone as well. Children who received azithromycin experienced fewer days of symptoms (3.4 days) as compared to those who received placebo (7.7 days; <i>p</i>&lt;0.0001); the biggest impact was noted when azithromycin was given before day 6 of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26704020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26704020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="42479b48-4c67-4b76-81a3-0a9cadc497dc">Rhinosinusitis, bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, bacterial:</b> Infants ≥6 months, Children, and Adolescents: Oral: 10 mg/kg/dose once daily for 3 days; maximum dose: 500 mg/dose; <b>Note:</b> Although FDA approved, macrolides are not recommended for empiric therapy due to high rates of resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23796742','lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23796742','lexi-content-ref-22438350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="002747a1-d12d-413d-9efb-492e8da1743e">Streptococcus, group A; pharyngitis/tonsillitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcus, group A; pharyngitis/tonsillitis (alternative agent for severe penicillin allergy): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Five-day regimen: </i>Children and Adolescents: Oral: 12 mg/kg/dose once daily for 5 days; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19246689','lexi-content-ref-15909262','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19246689','lexi-content-ref-15909262','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Three-day regimen</i>: Limited data available: Children and Adolescents: Oral: 20 mg/kg/dose once daily for 3 days; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15909262','lexi-content-ref-14770076','lexi-content-ref-8922571']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15909262','lexi-content-ref-14770076','lexi-content-ref-8922571'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="401febe1-ae0b-41a9-83e0-dfe2a941e5cf">Typhoid fever, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Typhoid fever (<i>Salmonella typhi</i> or <i>Salmonella paratyphi</i> infection), treatment:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: 10 mg/kg/dose (maximum dose: 500 mg/dose) once daily for 7 days <b>or</b> 20 mg/kg/dose (maximum dose: 1,000 mg/dose) once daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18493312','lexi-content-ref-11073741','lexi-content-ref-15034826','lexi-content-ref-17145784']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18493312','lexi-content-ref-11073741','lexi-content-ref-15034826','lexi-content-ref-17145784'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51073352"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b>Infants, Children, and Adolescents: Oral, IV:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Mild to severe impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, some experts suggest that no dosage adjustment is necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, some experts suggest no dosage adjustment or supplemental doses are necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, some experts suggest no dosage adjustment or supplemental doses are necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>). Based on adult information, azithromycin is not removed with continuous ambulatory peritoneal dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11587400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11587400'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous renal replacement therapy (CRRT):</b> There are no dosage adjustments provided in the manufacturer's labeling; however, some experts suggest no dosage adjustment or supplemental doses are necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51073353"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Azithromycin is predominantly hepatically eliminated; however, there is no dosage adjustment provided in the manufacturer's labeling. Use with caution due to potential for hepatotoxicity (rare); discontinue immediately for signs or symptoms of hepatitis.</p></div>
<div class="block doa drugH1Div" id="F7983294"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8868" href="/d/html/8868.html" rel="external">see "Azithromycin (systemic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5c4354e0-2178-427d-a042-9beb609e2523">Acne vulgaris, inflammatory, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris, inflammatory, moderate to severe (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use in combination with topical acne therapy. Reserve use for patients who cannot use preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Optimal dose uncertain; clinical trials have used varied pulse-dosing regimens: 500 mg once daily for 4 consecutive days per month for 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20666686','lexi-content-ref-11280457']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20666686','lexi-content-ref-11280457'])">Ref</a></span>) <b>or</b> 500 mg once daily for 3 days in the first week, followed by 500 mg once weekly until week 10 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21548512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21548512'])">Ref</a></span>) <b>or</b> 500 mg once daily for 3 consecutive days each week in month 1, followed by 500 mg once daily for 2 consecutive days each week in month 2, then 500 mg once daily for 1 day each week in month 3 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15807672']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15807672'])">Ref</a></span>). Treatment should ideally be limited to 3 to 4 months to minimize the risk of resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2c04f789-5b51-49cc-b68d-d3d58ad6925e">Babesiosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Babesiosis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild to moderate disease</i>: <b>Oral:</b> 500 mg on day 1, followed by 250 mg once daily in combination with atovaquone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33501959','lexi-content-ref-11078770']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33501959','lexi-content-ref-11078770'])">Ref</a></span>); higher doses of azithromycin (up to 1 g daily) may be used in patients who are highly immunocompromised (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33501959','lexi-content-ref-20047477']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33501959','lexi-content-ref-20047477'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe disease, initial therapy</i>: <b>IV:</b> 500 mg once daily in combination with atovaquone; may switch to oral azithromycin once symptoms improve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33501959','lexi-content-ref-27115378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33501959','lexi-content-ref-27115378'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe disease, oral step-down therapy</i>: <b>Oral:</b> 250 to 500 mg once daily in combination with atovaquone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33501959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33501959'])">Ref</a></span>). <b>Note:</b> Higher doses of azithromycin (up to 1 g daily) may be used in patients who are immunocompromised (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33501959','lexi-content-ref-27115378','lexi-content-ref-20047477']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33501959','lexi-content-ref-27115378','lexi-content-ref-20047477'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy:</i> 7 to 10 days; a longer duration of ≥6 weeks, including 2 weeks after resolution of parasitemia, may be necessary for patients at high risk of relapse (eg, patients who are highly immunocompromised) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33501959','lexi-content-ref-18181735','lexi-content-ref-27115378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33501959','lexi-content-ref-18181735','lexi-content-ref-27115378'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="452a5fca-911d-417a-b625-1b0f7a95ccab">
<i>Bartonella</i> spp. infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Bartonella</i> spp. infection (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients with HIV:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Treatment: </i>Note: </b>Not for treatment of endocarditis or CNS infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Bacillary angiomatosis, cat scratch disease, peliosis hepatitis, bacteremia, or osteomyelitis (alternative agent): <b>IV, Oral:</b> 500 mg once daily for ≥3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-Spach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-Spach.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Suppressive therapy:</b></i>
<b>Note: </b>For patients who experience a relapse after receiving a ≥3-month course of primary treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 500 mg once daily. Continue until patient has received ≥3 months of therapy and CD4 count is &gt;200 cells/mm<sup>3</sup> for ≥6 months; some experts discontinue only if <i>Bartonella </i>titers have also decreased 4-fold (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-Spach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-Spach.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients without HIV:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Cat scratch disease:</b></i></p>
<p style="text-indent:-2em;margin-left:8em;">Lymphadenitis: <b>Oral:</b> 500 mg as a single dose, then 250 mg once daily for 4 additional days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9655532','lexi-content-ref-24947530','lexi-content-ref-22391473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9655532','lexi-content-ref-24947530','lexi-content-ref-22391473'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Hepatosplenic disease, prolonged systemic illness: <b>IV,</b>
<b>Oral: </b>500 mg as a single dose, then 250 mg once daily in combination with rifampin for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spach.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spach.2'])">Ref</a></span>). For patients unable to tolerate rifampin, may give azithromycin monotherapy: 500 mg once daily for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25398062','lexi-content-ref-Spach.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25398062','lexi-content-ref-Spach.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">CNS infection, neuroretinitis (alternative agent): <b>IV, Oral: </b>500 mg as a single dose, then 250 mg once daily, in combination with rifampin. Duration is 10 to 14 days for CNS infection and 4 to 6 weeks for neuroretinitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spach.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spach.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1e6a8e1-33b3-4e95-8c93-a6451f585eb1">Bronchiectasis, prevention of pulmonary exacerbations</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchiectasis (noncystic fibrosis), prevention of pulmonary exacerbations (off-label use):</b>
<b>Oral:</b> 500 mg 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32303621','lexi-content-ref-22901887']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32303621','lexi-content-ref-22901887'])">Ref</a></span>) or 250 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23532241','lexi-content-ref-32303621']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23532241','lexi-content-ref-32303621'])">Ref</a></span>). An initial dose of 250 mg 3 times weekly, with subsequent titration according to patient response, may be considered to minimize adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32303621']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32303621'])">Ref</a></span>). <b>Note:</b> Recommended for patients with ≥2 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barker.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barker.2018'])">Ref</a></span>) or ≥3 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32303621','lexi-content-ref-28889110']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32303621','lexi-content-ref-28889110'])">Ref</a></span>) exacerbations per year; for those who do not have <i>Pseudomonas aeruginosa</i> infection, have <i>P. aeruginosa</i> but cannot take an inhaled antibiotic, or continue to have exacerbations despite an inhaled antibiotic. Screen patients for nontuberculous mycobacterial infection prior to treatment, and azithromycin should not be given if present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28889110']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28889110'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="71a43271-36bc-42e4-92e5-b854eb4370e4">Bronchiolitis obliterans</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchiolitis obliterans (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Bronchiolitis obliterans syndrome in lung transplant recipients, treatment:</i>
<b>Oral:</b> 250 mg 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32303621','lexi-content-ref-25359357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32303621','lexi-content-ref-25359357'])">Ref</a></span>); some experts recommend an initial dose of 250 mg <b>daily</b> for the first 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25359357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25359357'])">Ref</a></span>). Usually given for a 3-month trial period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32303621','lexi-content-ref-25359357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32303621','lexi-content-ref-25359357'])">Ref</a></span>), but some experts continue indefinitely, regardless of response to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pilewski.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pilewski.2018'])">Ref</a></span>). <b>Note:</b> When studied to prevent bronchiolitis obliterans syndrome in patients with hematologic malignancy who underwent allogeneic hematopoietic cell transplantation, rates of cancer relapse and mortality were increased among patients receiving long-term azithromycin, leading to early trial termination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28787506','lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28787506','lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Diffuse panbronchiolitis or symptomatic cryptogenic bronchiolitis obliterans, treatment:</i>
<b> Oral:</b> 250 to 500 mg once daily <b>or</b> 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27832694','lexi-content-ref-24255774','lexi-content-ref-King.2020','lexi-content-ref-21841323']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27832694','lexi-content-ref-24255774','lexi-content-ref-King.2020','lexi-content-ref-21841323'])">Ref</a></span>). After a 3- to 6-month trial, long-term therapy may be continued based on response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-King.1','lexi-content-ref-King.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-King.1','lexi-content-ref-King.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d19f87a-395d-4a1a-8cb4-24b53e0410d6">Cesarean delivery, preoperative prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cesarean delivery (intrapartum or after rupture of membranes), preoperative prophylaxis (off-label use): IV:</b> 500 mg as a single dose 1 hour prior to surgical incision; use in combination with standard preoperative antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30134425','lexi-content-ref-27682034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30134425','lexi-content-ref-27682034'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbd52e21-dcfe-472c-a480-3587971723ab">Chronic obstructive pulmonary disease, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, acute exacerbation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute exacerbation</i>
<i>, treatment</i>: <b>Note: </b>Avoid use in patients with risk factors for <i>Pseudomonas</i> infection or poor outcomes (eg, ≥65 years of age with major comorbidities, FEV<sub>1</sub> &lt;50% predicted, frequent exacerbations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sethi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sethi.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 500 mg in a single loading dose on day 1, followed by 250 mg once daily on days 2 to 5 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12749513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12749513'])">Ref</a></span>) <b> or</b> 500 mg once daily for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15725048']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15725048'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prevention of exacerbations</i>
<i>(off-</i>
<i>label use)</i>: <b>Note:</b> Consider for patients with frequent exacerbations despite optimal medical management (eg, &gt;3 exacerbations per year [at least 1 of which required hospital admission]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32303621']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32303621'])">Ref</a></span>) or (eg, ≥2 exacerbations per year or ≥1 hospital admission per year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ferguson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ferguson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 250 to 500 mg 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24229360','lexi-content-ref-32303621','lexi-content-ref-GOLD.1','lexi-content-ref-24746000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24229360','lexi-content-ref-32303621','lexi-content-ref-GOLD.1','lexi-content-ref-24746000'])">Ref</a></span>) <b>or</b> 250 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21864166','lexi-content-ref-GOLD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21864166','lexi-content-ref-GOLD.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c6fe0c8-be7d-4a6c-9b3f-edf21f0f80eb">Cystic fibrosis, anti-inflammatory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis, anti-inflammatory (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients with chronic pseudomonal infection or frequent exacerbations despite other therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23540878','lexi-content-ref-Simon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23540878','lexi-content-ref-Simon.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 250 mg (&lt;40 kg) or 500 mg (≥40 kg) 3 times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14519709']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14519709'])">Ref</a></span>) <b>or</b> 250 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11867823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11867823'])">Ref</a></span>). <b>Note:</b> Screen patients for nontuberculous mycobacterial infection prior to treatment and azithromycin should not be given if present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23540878','lexi-content-ref-14519709']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23540878','lexi-content-ref-14519709'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5d023e55-125d-4860-afd8-9934c605a1da">Diarrhea, infectious</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diarrhea, infectious (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Campylobacter gastroenteritis</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Patients with HIV: Mild to moderate disease (without bacteremia): <b>Oral: </b>500 mg once daily for 5 days. For patients with recurrent infection (particularly when CD4 &lt;200 cells/mm<sup>3</sup>), may extend therapy for 2 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients without HIV: <b>Oral: </b>1 g as a single dose (if nausea is a concern, 500 mg in 2 divided doses on same day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2','lexi-content-ref-28521004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2','lexi-content-ref-28521004'])">Ref</a></span>)) <b>or</b> 500 mg once daily for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27068718','lexi-content-ref-17205438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27068718','lexi-content-ref-17205438'])">Ref</a></span>). If symptoms have not resolved after 24 hours following single-dose therapy, continue with 500 mg once daily for 2 more days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27068718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27068718'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cholera (alternative agent)</i>: <b>Oral:</b> 1 g as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24944120','lexi-content-ref-16760445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24944120','lexi-content-ref-16760445'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Shigella gastroenteritis: </i>
<b>Note:</b> Confirm susceptibility if possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Agha.2018','lexi-content-ref-HHS.1','lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Agha.2018','lexi-content-ref-HHS.1','lexi-content-ref-WHO.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients with HIV (without bacteremia): <b>Oral: </b>500 mg once daily for 5 days. For patients with recurrent infection (particularly when CD4 &lt;200 cells/mm<sup>3</sup>), may extend therapy for up to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients without HIV: <b>Oral: </b>500 mg once daily for 3 days; for <i>Shigella dysenteriae</i> type 1 infection, treat for a total of 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27068718','lexi-content-ref-Agha.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27068718','lexi-content-ref-Agha.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Travelers' diarrhea</i>
<i>, empiric treatment</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Most cases are self-limited and may not warrant antimicrobial therapy. Some experts reserve antimicrobial therapy for severe diarrhea (eg, fever with blood, pus, or mucus in stool) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-LaRocque.1','lexi-content-ref-28521004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-LaRocque.1','lexi-content-ref-28521004'])">Ref</a></span>) or certain high-risk travelers (eg, those with an immunocompromising condition) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30913334','lexi-content-ref-LaRocque.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30913334','lexi-content-ref-LaRocque.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 1 g as a single dose <b>or</b> 500 mg once daily for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27068718','lexi-content-ref-30913334','lexi-content-ref-CDC.2','lexi-content-ref-28521004','lexi-content-ref-17205438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27068718','lexi-content-ref-30913334','lexi-content-ref-CDC.2','lexi-content-ref-28521004','lexi-content-ref-17205438'])">Ref</a></span>). If symptoms have not resolved after 24 hours following single-dose therapy, continue with 500 mg once daily for 2 more days. A 3-day course of 500 mg once daily is the preferred regimen for dysentery or febrile diarrhea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27068718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27068718'])">Ref</a></span>). Increased nausea may occur with the 1 g single-dose regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17205438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17205438'])">Ref</a></span>), which may be reduced by administering azithromycin as 2 divided doses on the same day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2','lexi-content-ref-28521004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2','lexi-content-ref-28521004'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="142a8701-080d-49cd-9f46-814412cd152f">Endocarditis, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, prophylaxis (invasive dental procedure) (alternative agent for penicillin-allergic patients) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for select situations (cardiac condition with the highest risk of adverse endocarditis outcomes and procedure likely to result in bacteremia with an organism that can cause endocarditis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33332150','lexi-content-ref-33853363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33332150','lexi-content-ref-33853363'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 mg 30 to 60 minutes prior to procedure; if inadvertently not given prior to the procedure, may be administered up to 2 hours after the procedure.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e096d904-52ea-4eb0-a6d7-1e796cc45b21">Lyme disease, erythema migrans</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lyme disease (<i>Borrelia</i> spp. infection), erythema migrans (alternative agent) (off-label use):</b>
<b>Oral:</b> 500 mg once daily for 7 days (range: 5 to 10 days). <b>Note:</b> Use with caution and only when recommended agents cannot be used (due to decreased efficacy compared to other agents) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3c1ffc1-3b2c-44e1-abea-6af15373b052">Mycobacterial infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mycobacterial (nontuberculous) infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycobacterium avium</i>
<i> complex (MAC) infection</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Disseminated disease in patients with HIV:</p>
<p style="text-indent:-2em;margin-left:8em;">Treatment: <b>Oral:</b> 500 to 600 mg daily as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Primary prophylaxis (patients with CD4 count &lt;50 cells/mm<sup>3 </sup>who are <b>not</b> initiated on fully suppressive antiretroviral therapy [ART]):<b> Oral:</b> 1.2 g once weekly (preferred) <b>or</b> 600 mg twice weekly; may discontinue prophylaxis when patient is initiated on effective ART (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-30043070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-30043070'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Secondary prophylaxis: <b>Oral:</b> 500 to 600 mg daily as part of an appropriate combination regimen; may discontinue when patient has completed ≥12 months of therapy, has no signs/symptoms of MAC disease, and has sustained (&gt;6 months) CD4 count &gt;100 cells/mm<sup>3</sup> in response to ART (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Pulmonary disease (nodular/bronchiectatic disease) (off-label use): <b>Oral:</b> 500 mg 3 times weekly as part of an appropriate combination regimen; continue treatment until patient is culture negative on therapy for ≥1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797222','lexi-content-ref-29054853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797222','lexi-content-ref-29054853'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Pulmonary disease (severe nodular/bronchiectatic or cavitary disease) (off-label use): <b>Oral:</b> 250 to 500 mg once daily as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797222','lexi-content-ref-29054853','lexi-content-ref-26810646','lexi-content-ref-22744719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797222','lexi-content-ref-29054853','lexi-content-ref-26810646','lexi-content-ref-22744719'])">Ref</a></span>); continue treatment until patient is culture negative on therapy for ≥1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797222','lexi-content-ref-29054853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797222','lexi-content-ref-29054853'])">Ref</a></span>). Preliminary data suggest a relationship between peak concentration and clinical outcome among patients receiving daily therapy for pulmonary MAC (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27480854']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27480854'])">Ref</a></span>); as such, some experts recommend checking levels and/or using the higher dose (eg, 500 mg once daily) of azithromycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kasperbauer.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kasperbauer.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Pulmonary disease in patients with cystic fibrosis (off-label use): <b>Oral:</b> 250 to 500 mg once daily as part of an appropriate combination regimen; continue treatment until patient is culture negative on therapy for ≥1 year. <b>Note:</b> Intermittent dosing (3 times weekly) is not recommended for patients with cystic fibrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26666259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26666259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycobacterial (nontuberculous, rapidly growing) infection (off-label use)</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Presence of inducible <i>erm</i> gene can result in decreased susceptibility even with a “susceptible” MIC result; perform susceptibility testing before and after ≥14 days of clarithromycin incubation to evaluate for the presence of an active <i>erm</i> gene, which may preclude use of azithromycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797222','lexi-content-ref-26666259','lexi-content-ref-Griffith.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797222','lexi-content-ref-26666259','lexi-content-ref-Griffith.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Pulmonary, skin and soft tissue, or bone infection: <b>Oral:</b> 250 to 500 mg once daily as part of an appropriate combination regimen and continued for ≥6 to 12 months for pulmonary and bone infections, and ≥4 months for skin and soft tissue infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797222','lexi-content-ref-26666259','lexi-content-ref-Griffith.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797222','lexi-content-ref-26666259','lexi-content-ref-Griffith.2018'])">Ref</a></span>). <b>Note:</b> Patients should be under the care of a clinician with expertise in managing mycobacterial infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797222'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c43d016-c199-4561-bd12-4713812696da">Pertussis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pertussis (off-label use):</b>
<b></b></p>
<p style="text-indent:0em;margin-left:2em;">
<b>Note:</b> Initiate antibiotic therapy within 3 weeks of cough onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>500 mg on day 1, followed by 250 mg once daily on days 2 to 5 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16340941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16340941'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed599b2f-52de-47cd-b7d2-d706008b1db0">Pneumonia, community-acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Outpatient: <b>Oral:</b> 500 mg on day 1, followed by 250 mg once daily for 4 days <b>or</b> 500 mg once daily for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9869584','lexi-content-ref-31573350','lexi-content-ref-1662637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9869584','lexi-content-ref-31573350','lexi-content-ref-1662637'])">Ref</a></span>). <b>Note:</b> May use as monotherapy (alternative agent) for outpatients without comorbidities or risk factors for antibiotic-resistant pathogens only if local pneumococcal resistance is &lt;25%. Must be used as part of an appropriate combination regimen in outpatients with comorbidities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350'])">Ref</a></span>); some experts prefer to use as part of an appropriate combination regimen in all outpatients, regardless of comorbidities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-File.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-File.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Inpatient: <b>Oral, IV:</b> 500 mg once daily for a minimum of 3 days, as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350','lexi-content-ref-File.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350','lexi-content-ref-File.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1437b55a-5145-4c15-bba4-c28709c37109">Rhinosinusitis, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>In uncomplicated acute bacterial rhinosinusitis, initial observation and symptom management without antibiotic therapy is appropriate in most patients. Reserve antibiotic therapy for poor follow-up or lack of improvement over the observation period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25832968','lexi-content-ref-26785402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25832968','lexi-content-ref-26785402'])">Ref</a></span>). Given increased resistance in <i>S. pneumoniae</i>, macrolides, including azithromycin, are not recommended for empiric treatment of acute bacterial rhinosinusitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25832968','lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25832968','lexi-content-ref-22438350'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>500 mg once daily for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8597b7bf-d38b-46ed-ae30-27103563bc5c">Sexually transmitted infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sexually transmitted infections:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cervical infection, empiric therapy for cervicitis or pathogen-directed therapy for Chlamydia trachomatis (alternative agent):</i>
<b>Oral:</b> 1 g as a single dose, preferably under direct observation; give in combination with ceftriaxone if the patient is at high risk for gonorrhea, if follow-up is a concern, or if the local prevalence of gonorrhea is high (eg, &gt;5%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Powell.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Powell.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chancroid </i>
<i>(due to </i>
<i>Haemophilus ducreyi</i>
<i>)</i>: <b>Oral:</b> 1 g as a single dose. <b>Note:</b> Data are limited concerning efficacy in HIV infected patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gonococcal infection, uncomplicated (infection of the cervix, rectum [off-label use], or urethra</i>
<i>) (alternative agent):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Reserve for patients who cannot use a cephalosporin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-36701253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-36701253'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 2 g as a single dose in combination with IM gentamicin (preferred) or oral gemifloxacin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Sena.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Sena.1'])">Ref</a></span>). When treatment failure is suspected (eg, detection of <i>N. gonorrhoeae</i> after treatment without additional sexual exposure), consult an infectious diseases specialist. Report failures to the CDC through state and local health departments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Granuloma inguinale (donovanosis) (off-label use)</i>: <b>Oral:</b> 1 g once weekly <b>or</b> 500 mg once daily for &gt;3 weeks and until resolution of lesions. <b>Note:</b> If symptoms do not improve within the first few days of therapy, the addition of a second agent may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lymphogranuloma venereum (alternative agent) (off-label use):</i>
<b>Oral:</b> 1 g once weekly for 3 weeks. <b>Note:</b> Consider a test of cure for <i>C. trachomatis</i> 4 weeks after therapy completion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycoplasma genitalium</i>
<i>(alternative agent)</i>
<i>(off-label use): </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Azithromycin resistance is rapidly emerging; the CDC only recommends azithromycin for documented susceptible infection, but susceptibility testing is not widely available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 1 g on day 1, followed by 500 mg once daily on days 2 through 4 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-31629365','lexi-content-ref-29873691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-31629365','lexi-content-ref-29873691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pelvic inflammatory disease, mild to moderate (alternative agent): </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Reserve for patients who cannot use first-line options and are unlikely to have infection caused by <i>N. gonorrhoeae</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Wiesenfeld.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Wiesenfeld.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral, IV: </b>500 mg IV once daily for 1 to 2 days, then 250 mg orally once daily to complete a 7-day course, in combination with metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12635534','lexi-content-ref-34292926','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12635534','lexi-content-ref-34292926','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urethral infection, empiric therapy for urethritis or pathogen-directed therapy for Chlamydia trachomatis (alternative agent):</i>
<b>Oral:</b> 1 g as a single dose, preferably under direct observation <b>or</b> 500 mg on day 1 then 250 mg once daily for 4 days (some experts prefer this dose for urethritis if adherence is not a concern (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bachmann.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bachmann.2018'])">Ref</a></span>)); give in combination with ceftriaxone if there is microscopic evidence of gonococcal urethritis or if there is high clinical suspicion of gonococcal infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bachmann.2018','lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bachmann.2018','lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3f2098d-7a15-436e-bc6b-422791b57466">
<i>Streptococcus</i>, group A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Streptococcus</i>, group A (alternative agent for patients with severe penicillin allergy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pharyngitis: </i>
<b>Oral:</b> 12 mg/kg (maximum: 500 mg) on day 1, followed by 6 mg/kg (maximum: 250 mg) once daily on days 2 through 5 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22965026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22965026'])">Ref</a></span>) <b>or</b> 12 mg/kg (maximum: 500 mg) once daily for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pichichero.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pichichero.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Secondary prophylaxis in patients with rheumatic fever (prevention of recurrent attacks) (off-label use):</i>
<b>Note:</b> Optimal dose not well defined (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19246689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19246689'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>250 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pichichero.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pichichero.1'])">Ref</a></span>). Duration depends on risk factors, age, and presence of valvular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19246689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19246689'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="22ab2cb7-13ce-4347-b3ac-2c0b642f1f99">Surgical prophylaxis, uterine evacuation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis, uterine evacuation (induced abortion or pregnancy loss) (alternative agent) (off-label use): Oral:</b> 500 mg as a single dose 1 hour before the procedure; may be administered up to 24 hours before the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Shih.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Shih.2019'])">Ref</a></span>). <b>Note:</b> The optimal dosing regimen has not been established; various protocols are in use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29665357','lexi-content-ref-30125557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29665357','lexi-content-ref-30125557'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c03ac77-1414-4c80-86ea-b2d6e8ba19e0">Typhoid and paratyphoid fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Typhoid and paratyphoid fever (<i>S. typhi</i> or <i>S. paratyphi</i> infection), uncomplicated, treatment (off-label use): Oral:</b> 1 g once daily <b>or </b>1 g once on day 1, followed by 500 mg once daily; total duration: 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10858343','lexi-content-ref-18493312','lexi-content-ref-10348767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10858343','lexi-content-ref-18493312','lexi-content-ref-10348767'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990585"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral, IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8655206']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8655206'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: No dosage adjustment or supplemental dose necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-19397464'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis: Minimally dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11587400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11587400'])">Ref</a></span>): No dosage adjustment or supplemental dose necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25859365']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25859365'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CRRT: No dosage adjustment or supplemental dose necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-19397464'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987950"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Azithromycin is predominantly hepatically eliminated; however, there is no dosage adjustment provided in the manufacturer's labeling. Use with caution due to potential for hepatotoxicity (rare); discontinue immediately for signs or symptoms of hepatitis.</p></div>
<div class="block arsc drugH1Div" id="F54972615"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Altered cardiac conduction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Azithromycin is associated with altered cardiac conduction, including <b>prolonged QT interval on ECG</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14615808','lexi-content-ref-16856707','lexi-content-ref-11707055','lexi-content-ref-20391905']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14615808','lexi-content-ref-16856707','lexi-content-ref-11707055','lexi-content-ref-20391905'])">Ref</a></span>) and polymorphic <b>ventricular tachycardia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16359290','lexi-content-ref-28408648']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16359290','lexi-content-ref-28408648'])">Ref</a></span>). May be associated with increased cardiac risk and/or death; however, data are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25558301','lexi-content-ref-17420199','lexi-content-ref-25748818','lexi-content-ref-25494485','lexi-content-ref-24893087','lexi-content-ref-24615307','lexi-content-ref-22591294','lexi-content-ref-23635050','lexi-content-ref-32585019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25558301','lexi-content-ref-17420199','lexi-content-ref-25748818','lexi-content-ref-25494485','lexi-content-ref-24893087','lexi-content-ref-24615307','lexi-content-ref-22591294','lexi-content-ref-23635050','lexi-content-ref-32585019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Inhibits the delayed rectifier potassium channel, which is encoded by the human ether-à-go-go related gene 1 (hERG1) with much less affinity than erythromycin, causing prolonging of the action potential of cardiac myocytes, prolonging the QT interval (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24001961','lexi-content-ref-25165550','lexi-content-ref-12235254','lexi-content-ref-25299875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24001961','lexi-content-ref-25165550','lexi-content-ref-12235254','lexi-content-ref-25299875'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Variable; altered cardiac conduction reported to occur within minutes after the administration of the first dose up to 7 days after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25165550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25165550'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25165550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25165550'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25748818','lexi-content-ref-25165550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25748818','lexi-content-ref-25165550'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Heart disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25165550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25165550'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High baseline cardiovascular disease risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25748818','lexi-content-ref-22591294']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25748818','lexi-content-ref-22591294'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of drug-induced torsades de pointes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Congenital long QT syndrome (LQTS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline QTc interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 milliseconds (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Coadministration of medications that prolong the QT interval or drug interactions that increase serum drug concentrations of QT prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25165550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25165550'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypokalemia and hypomagnesemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25165550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25165550'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25165550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25165550'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Clostridioides difficile infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>Clostridioides difficile</i> infection (CDI) has been reported with azithromycin, including <b>
<i>Clostridioides difficile</i> associated diarrhea</b> and <b>
<i>Clostridioides difficile</i> colitis</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Variable; may start on the first day of antibiotic therapy or up to 3 months postantibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22146873','lexi-content-ref-29053792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22146873','lexi-content-ref-29053792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Antibiotic exposure (highest risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Type of antibiotic (azithromycin considered moderate risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478961','lexi-content-ref-23620467']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478961','lexi-content-ref-23620467'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long durations in a hospital or other healthcare setting (recent or current) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunocompromised conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• A serious underlying condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• GI surgery/manipulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29462280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29462280'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antiulcer medications (eg, proton pump inhibitors and H2 blockers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Drug-induced liver injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Azithromycin is associated with drug-induced liver injury, including <b>cholestatic hepatitis, hepatocellular hepatitis, </b>and mixed cholestatic/hepatocellular hepatitis<b>. </b>Most patients fully recover; however, severe cutaneous reactions, chronic liver injury, and serious complications leading to death or liver transplantation may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25111234']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25111234'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non-dose-related; not fully understood. An in vitro study was unable to predict if the mechanism was related to bile acid transporter inhibition, mitochondrial dysfunction, or oxidative stress and concluded that hepatotoxicity could be caused by a mechanism that was not evaluated or could be due to unknown metabolite effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30734107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30734107'])">Ref</a></span>). May be related to hypersensitivity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25111234']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25111234'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; typically occurs within 1 to 3 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25111234']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25111234'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Underlying chronic liver disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25111234']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25111234'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypersensitivity to azithromycin; cross-reactivity among macrolides may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11247598','lexi-content-ref-25111234','lexi-content-ref-31540456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11247598','lexi-content-ref-25111234','lexi-content-ref-31540456'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Delayed hypersensitivity reactions have been reported with azithromycin, ranging from maculopapular <b>skin rash</b> and fixed drug eruption to severe cutaneous adverse reactions (SCARs). SCARs include <b>acute generalized exanthematous pustulosis</b>, <b>drug reaction with eosinophilia and systemic symptoms</b>, <b>Stevens-Johnson syndrome</b> and <b>toxic epidermal necrolysis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28726337','lexi-content-ref-18991703','lexi-content-ref-25997306','lexi-content-ref-28497632','lexi-content-ref-11247598','lexi-content-ref-25754159','lexi-content-ref-25784092','lexi-content-ref-26997729','lexi-content-ref-26194400','lexi-content-ref-19189924','lexi-content-ref-25297051','lexi-content-ref-29505509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28726337','lexi-content-ref-18991703','lexi-content-ref-25997306','lexi-content-ref-28497632','lexi-content-ref-11247598','lexi-content-ref-25754159','lexi-content-ref-25784092','lexi-content-ref-26997729','lexi-content-ref-26194400','lexi-content-ref-19189924','lexi-content-ref-25297051','lexi-content-ref-29505509'])">Ref</a></span>). Azithromycin has also been associated with development of a maculopapular rash in patients with concurrent infectious mononucleosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25302218','lexi-content-ref-12587634','lexi-content-ref-27620494']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25302218','lexi-content-ref-12587634','lexi-content-ref-27620494'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non-dose-related; immunologic; delayed hypersensitivity reactions, including SCARs, involve a T-cell mediated drug-specific immune response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549'])">Ref</a></span>). The mechanism for the development of a nonspecific rash in patients with infectious mononucleosis may be a transient virus-mediated immune alteration that leads to the development of a reversible hypersensitivity reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27620494']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27620494'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Variable; type IV reactions are delayed hypersensitivity reactions that typically occur days to weeks after drug exposure but may occur more rapidly (usually within 1 to 4 days) upon reexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2014'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Limited information regarding cross-reactivity among macrolides (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28497632']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28497632'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate hypersensitivity reactions, including <b>angioedema</b>, <b>urticaria </b>and <b>anaphylaxis</b>, have been reported with azithromycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18991703','lexi-content-ref-25997306','lexi-content-ref-24674687','lexi-content-ref-28923488']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18991703','lexi-content-ref-25997306','lexi-content-ref-24674687','lexi-content-ref-28923488'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non-dose-related; immunologic. Although IgE has not been identified in relationship to immediate hypersensitivity reactions to azithromycin, most immediate hypersensitivity reactions are IgE-mediated, with specific antibodies formed against a drug allergen following initial exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; generally occurs within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-NICE.2014'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Limited information regarding cross-reactivity among macrolides (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24674687','lexi-content-ref-21130389','lexi-content-ref-28923488']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24674687','lexi-content-ref-21130389','lexi-content-ref-28923488'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ototoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Azithromycin is associated with ototoxicity, including <b>hearing loss</b> and <b>tinnitus</b>. Ototoxicity usually manifests in bilateral symmetrical hearing loss of 40 to 50 dB. In most cases, ototoxicity is reversible and resolves within 1 to 5 weeks after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9142801','lexi-content-ref-28002638','lexi-content-ref-33080070','lexi-content-ref-33767665','lexi-content-ref-7904701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9142801','lexi-content-ref-28002638','lexi-content-ref-33080070','lexi-content-ref-33767665','lexi-content-ref-7904701'])">Ref</a></span>). Irreversible hearing loss has been reported, albeit rarely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28002638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28002638'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; linked to cumulative doses of azithromycin. Azithromycin may exert temporary ototoxic effects on outer hair cells via reversible reduction in transient evoked otoacoustic emissions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9142801','lexi-content-ref-8994766','lexi-content-ref-11535141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9142801','lexi-content-ref-8994766','lexi-content-ref-11535141'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; reported cases of tinnitus have occurred as early as 24 hours; however, the majority of hearing loss cases have occurred with prolonged durations of therapy (ie, ≥4 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28002638','lexi-content-ref-10778901','lexi-content-ref-7904701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28002638','lexi-content-ref-10778901','lexi-content-ref-7904701'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Generally greater with higher doses (ie, 500 to 600 mg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9142801','lexi-content-ref-8994766']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9142801','lexi-content-ref-8994766'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged durations of therapy (ie, ≥4 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9142801','lexi-content-ref-8994766','lexi-content-ref-7904701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9142801','lexi-content-ref-8994766','lexi-content-ref-7904701'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Serum azithromycin levels of ≥0.8 +/- 0.4 µg/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9142801']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9142801'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F7983244"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Diarrhea (≤14%; high single-dose regimens tend to be associated with increased incidence), nausea (≤7%; high single-dose regimens: 5% to 18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (≤1%), facial edema (children: ≤1%), palpitations (adults: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (children: ≤1%), eczema (children: ≤1%), fungal dermatitis (children: ≤1%), pruritus (≤2%), skin photosensitivity (adults: ≤1%), skin rash (≤2%; single-dose regimens tend to be associated with increased incidence), urticaria (≤1%), vesiculobullous dermatitis (children: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased lactate dehydrogenase (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (1% to 7%; single-dose regimens tend to be associated with increased incidence), anorexia (≤2%), constipation (≤1%), dysgeusia (adults: ≤1%), dyspepsia (≤1%), enteritis (children: ≤1%), flatulence (≤1%), gastritis (≤1%), melena (adults: ≤1%), oral candidiasis (≤1%), stomatitis (≤1%), vomiting (adults: ≤2%; adults, single 2 g dose: 2% to 7%; children, single-dose regimens tend to be associated with increased incidence: 1% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Genital candidiasis (adults: ≤1%), vaginitis (adults: ≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal infection (children: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local inflammation (adults, IV: 3%), pain at injection site (adults, IV: 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (≤1%), dizziness (≤1%), drowsiness (≤1%), fatigue (≤1%), headache (≤1%), insomnia (children: ≤1%), malaise (children: ≤1%), nervousness (children: ≤1%), pain (children: ≤1%), vertigo (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hyperkinetic muscle activity (children: ≤1%), increased creatine phosphokinase in blood specimen (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (≤1%), cough (children: ≤1%), pleural effusion (children: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children: ≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Prolonged QT interval on ECG (rare: &lt;1%) (Russo 2006), syncope (Cocco 2015), torsades de pointes (rare: &lt;1%) (Kezerashvili 2007), ventricular tachycardia (rare: &lt;1%) (Kim 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (rare: &lt;1%) (Campanón-Toro 2017), erythema multiforme (Isik 2007), Stevens-Johnson syndrome (rare: &lt;1%) (Xu 2018), toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia (Schiffman 2018), <span class="organism">Clostridioides difficile</span> associated diarrhea (rare: &lt;1%) (Brown 2013), <span class="organism">Clostridioides difficile</span> colitis (rare: &lt;1%) (Brown 2013), pancreatitis, pyloric stenosis (infantile hypertrophic) (Smith 2015), tongue discoloration</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (Butt 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis (rare: &lt;1%) (Martinez 2015), hepatic failure (rare: &lt;1%) (Martinez 2015), hepatic necrosis (rare: &lt;1%) (Martinez 2015), hepatocellular hepatitis (rare: &lt;1%) (Martinez 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (rare: &lt;1%) (Ünal 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (rare: &lt;1%) (Sriratanaviriyakul 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, altered sense of smell (Schiffman 2018), anosmia (Schiffman 2018), anxiety (Adachi 2003), exacerbation of myasthenia gravis (Pradhan 2009), hyperactive behavior, paresthesia, seizure (Schiff 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, asthenia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness (Etminan 2017), hearing loss (Li 2014), tinnitus (Tseng 1997)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, interstitial nephritis (Woodruff 2015)</p></div>
<div class="block coi drugH1Div" id="F7983221"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to azithromycin, erythromycin, other macrolide (eg, azalide or ketolide) antibiotics, or any component of the formulation; history of cholestatic jaundice/hepatic dysfunction associated with prior azithromycin use</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The manufacturer does not list concurrent use of pimozide as a contraindication; however, azithromycin is listed as a contraindication in the manufacturer's labeling for pimozide.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F7983222"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal superinfection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchiolitis obliterans: When studied to prevent bronchiolitis obliterans syndrome in patients with hematologic malignancy who underwent allogeneic hematopoietic cell transplantation, rates of cancer relapse and mortality were increased among patients receiving long-term azithromycin, leading to early trial termination (Bergeron 2017; FDA Drug Safety Communication 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Gonorrhea/syphilis: May mask or delay symptoms of incubating gonorrhea or syphilis, so appropriate culture and susceptibility tests should be performed prior to initiating a treatment regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation and new onset of symptoms have occurred.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Infants: Use of azithromycin in neonates and infants &lt;6 weeks of age has been associated with infantile hypertrophic pyloric stenosis (IHPS); the strongest association occurred with exposure during the first 2 weeks of life; observe for nonbilious vomiting or irritability with feeding (Eberly 2015). The risks and benefits of azithromycin use should be carefully considered in neonates; some experts recommend avoidance except for in the treatment of pertussis or <i>C. trachomatis</i> pneumonia; specific risk-benefit ratio should be considered before use for <i>Ureaplasma</i> spp. eradication (Meyers 2020).</p></div>
<div class="block foc drugH1Div" id="F7983340"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zithromax: 1 g (3 ea, 10 ea) [cherry-banana flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea, 3 ea, 10 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zithromax: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zithromax: 100 mg/5 mL (15 mL) [cherry-vanilla-banana flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zithromax: 200 mg/5 mL (15 mL, 22.5 mL, 30 mL) [cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/5 mL (15 mL); 200 mg/5 mL (15 mL, 22.5 mL, 30 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zithromax: 250 mg, 500 mg, 600 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zithromax Tri-Pak: 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zithromax Z-Pak: 250 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg, 600 mg</p></div>
<div class="block geq drugH1Div" id="F7983186"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F7983342"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Azithromycin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $29.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Zithromax Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $29.64</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Azithromycin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $3.60 - $17.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Zithromax Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $7.31</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Azithromycin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $2.33</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/5 mL (per mL): $1.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Zithromax Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $2.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/5 mL (per mL): $2.71</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Azithromycin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $7.77 - $7.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $15.54 - $15.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg (per each): $8.05 - $18.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Zithromax Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $2.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $3.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Zithromax Tri-Pak Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $83.62</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Zithromax Z-Pak Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $2.59</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869062"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zithromax: 500 mg (5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zithromax: 100 mg/5 mL (15 mL); 200 mg/5 mL (15 mL, 22.5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/5 mL (15 mL, 22.5 mL); 200 mg/5 mL (15 mL, 22.5 mL, 37.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zithromax: 250 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 600 mg</p></div>
<div class="block admp drugH1Div" id="F52614315"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer without regard to food; do not administer with antacids that contain aluminum or magnesium.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension bottle: Shake well before use.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension 1,000 mg packet for a single dose: Mix the entire contents of the packet with approximately 60 mL of water. Administer the entire contents immediately after mixing; add an additional 60 mL of water, mix, and drink. Do not use to administer any other dose except 1,000 mg.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: <b>Do not give IM or by IV bolus.</b> Administer IV infusion at a final concentration of 1 mg/mL over 3 hours; for a 2 mg/mL concentration, infuse over 1 hour; do not infuse over a period of less than 60 minutes.</p></div>
<div class="block adm drugH1Div" id="F7983300"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over 1 hour (2 mg/ml infusion) or over 3 hours (1 mg/ml infusion). Not for IM or IV bolus administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Suspension and tablet may be taken without regard to food. Shake suspension well before each use.</p></div>
<div class="block sts drugH1Div" id="F7983256"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store intact vials of injection at room temperature. Reconstituted solution is stable for 24 hours when stored below 30°C (86°F). The diluted solution D5W, D5LR, D5<sup>1</sup>/<sub>4</sub>NS, D5<sup>1</sup>/<sub>3</sub>NS, D5<sup>1</sup>/<sub>2</sub>NS (with or without 20 mEq/L KCl), Normosol-M in D5, Normosol-R in D5, LR, NS, or <sup>1</sup>/<sub>2</sub>NS is stable for 24 hours at or below room temperature (30°C [86°F]) and for 7 days if stored under refrigeration (5°C [41°F]).</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Store dry powder below 30°C (86°F). Store reconstituted suspension at 5°C to 30°C (41°F to 86°F) and use within 10 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet: Store between 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53570418"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension (100 mg per 5 mL; 200 mg per 5 mL), tablets (250 and 500 mg): Treatment of acute otitis media due to <i>Haemophilus influenzae</i>, <i>Moraxella catarrhalis</i>, or <i>Streptococcus pneumoniae</i> (FDA approved in pediatric patients ages ≥6 months); treatment of community-acquired pneumonia due to <i>Chlamydia (Chlamydophila) pneumoniae, Mycoplasma pneumoniae, H. influenzae</i>, or <i>S. pneumoniae</i> in patients appropriate for oral therapy (FDA approved in ages ≥6 months and adults); treatment of pharyngitis/tonsillitis due to <i>Streptococcus pyogenes</i> in individuals who cannot use first-line therapy (FDA approved in ages ≥2 years and adults); treatment of acute bacterial sinusitis or acute exacerbations of chronic bronchitis due to <i>H. influenzae</i>, <i>M. catarrhalis</i>, or <i>S. pneumoniae</i> (FDA approved in adults); treatment of uncomplicated skin and skin structure infections due to <i>Staphylococcus aureus</i>, <i>S. pyogenes</i>, or <i>Streptococcus agalactiae</i> (FDA approved in adults); treatment of urethritis and cervicitis due to <i>Chlamydia trachomatis</i> or <i>Neisseria gonorrhoeae</i> (FDA approved in adults); treatment of chancroid (FDA approved in adult males). Has also been used for treatment of babesiosis, bartonellosis, cholera, cystic fibrosis lung disease, infectious diarrhea, pertussis, typhoid fever, endocarditis prophylaxis in penicillin allergic patients, prophylaxis of peritonitis in patients undergoing invasive dental procedures, and chemoprophylaxis for meningococcal disease in high-risk contact.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension (1,000 mg per 5 mL packet), tablet (600 mg): Treatment of urethritis and cervicitis due to <i>C. trachomatis</i>; prevention of disseminated <i>Mycobacterium avium</i> complex (MAC) disease; treatment of disseminated MAC disease in combination with ethambutol (All indications: FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Treatment of community-acquired pneumonia due to susceptible <i>C. pneumoniae</i>, <i>Legionella pneumophila</i>, <i>M. pneumoniae</i>, <i>H. influenzae</i>, <i>S. aureus</i>, <i>S. pneumoniae</i>; treatment of pelvic inflammatory disease due to susceptible <i>C. trachomatis</i>, <i>N. gonorrhoeae</i>, or <i>Mycoplasma hominis</i> (All indications: FDA approved in ≥16 years and adults).</p></div>
<div class="block mst drugH1Div" id="F7983163"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Azithromycin may be confused with azathioprine, erythromycin</p>
<p style="text-indent:-2em;margin-left:4em;">Zithromax may be confused with Fosamax, Zinacef, Zovirax</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Azithromycin (systemic), when used in neonates, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be avoided due to risk of hypertrophic pyloric stenosis, unless treating <i>Bordetella pertussis </i>or <i>Chlamydia trachomatis </i>pneumonia; risk vs benefit should be assessed when using for <i>Ureaplasma</i>
<i>spp.</i>(strong recommendation; high quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F7983249"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> P-glycoprotein/ABCB1</p></div>
<div class="block dri drugH1Div" id="F7983250"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: If combined, administer the P-gp inhibitor simultaneously with, or after, the dose of afatinib. Monitor closely for signs and symptoms of afatinib toxicity and if the combination is not tolerated, reduce the afatinib dose by 10 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Berotralstat.  Management: Decrease the berotralstat dose to 110 mg daily when combined with P-glycoprotein (P-gp) inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Macrolide Antibiotics may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Chloroquine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Clofazimine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: This combination is often contraindicated, but combined use may be permitted with dose adjustment and monitoring. Recommendations vary based on brand, indication, use of CYP3A4 inhibitors, and hepatic/renal function. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Azithromycin (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Dabrafenib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Liposomal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Azithromycin (Systemic) may increase the serum concentration of Edoxaban.  Management: In patients treated for DVT/PE, reduce the edoxaban dose to 30mg daily when combined with azithromycin. No dose adjustment is recommended for patients treated for atrial fibrillation. Monitor for increased edoxaban toxicities (ie, bleeding) when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gadobenate Dimeglumine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Gadobenate Dimeglumine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Halofantrine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydroxychloroquine: Azithromycin (Systemic) may enhance the cardiotoxic effect of Hydroxychloroquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotuzumab Ozogamicin: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Inotuzumab Ozogamicin.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Larotrectinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin tablets with P-glycoprotein/ABCB1 inhibitors. If concomitant use is required, monitor for lefamulin adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Lofexidine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: Azithromycin (Systemic) may enhance the myopathic (rhabdomyolysis) effect of Lovastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Midostaurin.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mizolastine: Macrolide Antibiotics may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Morphine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Nadolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: May increase the serum concentration of Azithromycin (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Ondansetron.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: Azithromycin (Systemic) may enhance the QTc-prolonging effect of PAZOPanib. Azithromycin (Systemic) may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Piperaquine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probucol: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Probucol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of Azithromycin (Systemic). Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): Azithromycin (Systemic) may enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Class IC Antiarrhythmics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Azithromycin (Systemic). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of Azithromycin (Systemic). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ranolazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: Azithromycin (Systemic) may enhance the myopathic (rhabdomyolysis) effect of Red Yeast Rice. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix.  Management: Avoid coadministration of relugolix with oral P-gp inhibitors whenever possible. If combined, take relugolix at least 6 hours prior to the P-gp inhibitor and monitor patients more frequently for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix, Estradiol, and Norethindrone.  Management: Avoid use of relugolix/estradiol/norethindrone with P-glycoprotein (P-gp) inhibitors. If concomitant use is unavoidable, relugolix/estradiol/norethindrone should be administered at least 6 hours before the P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rimegepant.  Management: Avoid administration of another dose of rimegepant within 48 hours if given concomitantly with a P-glycoprotein (P-gp) inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Azithromycin (Systemic) may enhance the QTc-prolonging effect of RisperiDONE. Azithromycin (Systemic) may increase the serum concentration of RisperiDONE.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RomiDEPsin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Systemic): Azithromycin (Systemic) may increase the serum concentration of Ruxolitinib (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: Azithromycin (Systemic) may enhance the myopathic (rhabdomyolysis) effect of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Conventional).  Management: Avoid concurrent use of sirolimus with P-glycoprotein (P-gp) inhibitors when possible and alternative agents with lesser interaction potential with sirolimus should be considered. Monitor for increased sirolimus concentrations/toxicity if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Azithromycin (Systemic) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Talazoparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tegaserod (Withdrawn from US Market): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tegaserod (Withdrawn from US Market). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Teniposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Disoproxil Fumarate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and second dose (at least 2 hours later if needed) of 50 mg when used with a P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Macrolide Antibiotics may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F7983299"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;">Some products may contain sodium and/or sucrose.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension may be administered with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet may be administered with food to decrease GI effects.</p></div>
<div class="block pri drugH1Div" id="F7983215"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Azithromycin crosses the placenta and is present in amniotic fluid (Boelig 2021; Ramsey 2003; Sutton 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of azithromycin during pregnancy are available (Andersson 2021; Hume-Nixon 2021; Keskin-Arslan 2023; Leke 2021; Mallah 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Some pharmacokinetic properties of azithromycin may be altered during pregnancy (Fischer 2012; Ramsey 2003; Saiman 2010; Sutton 2015). High concentrations of azithromycin are sustained in the myometrium and adipose tissue when given as a single dose prior to cesarean delivery (Ramsey 2003; Sutton 2015). Following a single dose in patients with preterm premature rupture of membranes, azithromycin amniotic fluid concentrations may fall below the MIC for common pathogens within 7 days (Boelig 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Azithromycin may be used as an alternative or adjunctive prophylactic antibiotic in patients undergoing unplanned cesarean delivery (ACOG 2018b). Azithromycin may also be administered to patients with preterm prelabor rupture of membranes (ACOG 2020; SOGC [Ronzoni 2022]). Azithromycin is recommended for the treatment of several infections, including chlamydia, and granuloma inguinale, and prophylaxis of <i>Mycobacterium avium</i> complex in select pregnant patients (consult current guidelines) (CDC [Workowski 2021]; HHS [OI adult] 2023). Azithromycin may also be used in certain situations prior to vaginal delivery in patients at high risk for endocarditis (ACOG 2018a; ACOG 2018b). Azithromycin may be useful for lymphogranuloma venereum during pregnancy; however, dosing and duration of therapy have not been specifically studied in pregnant patients. The treatment of cervicitis in pregnancy is the same as nonpregnant patients (CDC [Workowski 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Azithromycin is used as an alternative treatment of Lyme disease. Vertical transmission from mother to fetus is not well documented; it is unclear if infection increases the risk of adverse pregnancy outcomes. When treatment for Lyme disease in pregnancy is needed, the indications and dosing of azithromycin are the same as in nonpregnant patients (IDSA/AAN/ACR [Lantos 2021]; Lambert 2020; SOGC [Smith 2020]).</p></div>
<div class="block mopp drugH1Div" id="F53570397"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">LFTs, CBC with differential; ECG for QT prolongation. Monitor for signs and symptoms of infantile hypertrophic pyloric stenosis (eg, post-prandial nonbilious vomiting, feeding intolerance) in patients &lt;6 weeks of age (Eberly 2015).</p></div>
<div class="block pha drugH1Div" id="F7983260"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits RNA-dependent protein synthesis at the chain elongation step; binds to the 50S ribosomal subunit resulting in blockage of transpeptidation</p></div>
<div class="block phk drugH1Div" id="F7983262"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapid from the GI tract.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Extensive tissue; distributes well into skin, lungs, sputum, tonsils, and cervix; penetration into CSF is poor; V<sub>d</sub>: 31 to 33 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding (concentration dependent and dependent on alpha1-acid glycoprotein concentrations): Oral, IV: 7% to 51%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic to inactive metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: Tablet, oral suspension: 34% to 52%; variable effect with food (increased with oral suspension, unchanged with tablet).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: Oral, IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children 4 months to 15 years: 54.5 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 68 to 72 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: ~2 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Oral, IV: Biliary (major route 50%, unchanged); urine (6% to 14% unchanged).</p></div>
<div class="block phksp drugH1Div" id="F51153953"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: C<sub>max</sub> and AUC increased 61% and 35%, respectively, in subjects with severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: In elderly women, a higher C<sub>max</sub> was observed but there was no change in drug accumulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i> Concentration and time dependent, associated with AUC<sub>24</sub>/minimum inhibitory concentration; goal: ≥25 (Bauernfeind 1995; Craig 1998; Craig 2001; den Hollander 1998; Van Bambeke 2001).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expected drug exposure in normal renal function:</i></p>
<p style="text-indent:-2em;margin-left:6em;">AUC:</p>
<p style="text-indent:-2em;margin-left:8em;">Pediatric patients:</p>
<p style="text-indent:-2em;margin-left:10em;">Oral suspension: Multiple dose: 10 mg/kg/dose (maximum dose: 500 mg/dose) on day 1, followed by 5 mg/kg/dose (maximum dose: 250 mg/dose) daily on days 2 to 5.</p>
<p style="text-indent:-2em;margin-left:12em;">Infants ≥6 months of age and children ≤5 years of age: AUC<sub>24</sub>: 1.841 ± 0.651 mg•hour/L (Nahata 1995).</p>
<p style="text-indent:-2em;margin-left:12em;">Children ≥6 years of age and adolescents &lt;16 years of age: AUC<sub>24</sub>: 3.109 ± 1.033 mg•hour/L (Nahata 1993).</p>
<p style="text-indent:-2em;margin-left:10em;">IV: Infants ≥6 months of age, children, and adolescents &lt;16 years of age: Single dose: 10 mg/kg (maximum dose: 500 mg): AUC<sub>0-72</sub>: 8.2 ± 1.7 mg•hour/L (Jacobs 2005).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults:</p>
<p style="text-indent:-2em;margin-left:10em;">Oral tablet:</p>
<p style="text-indent:-2em;margin-left:12em;">Single dose, 500 mg: AUC<sub>0-72</sub>: 4.3 ± 1.2 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:12em;">Multiple dose (steady state): 500 mg once daily for 3 days: AUC<sub>0-∞</sub>: 17.4 ± 6.2 mg•hour/L; 500 mg day 1,250 mg once daily on days 2 to 5: AUC<sub>0-∞</sub>: 14.9 ± 3.1 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:10em;">IV: Single dose, 500 mg: AUC<sub>24</sub>: 8.03 ± 0.86 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect:</i> Gram-positive/gram-negative respiratory pathogens: ~2 to 4 hours, varies based on organism (Debbia 1990; Ferrara 1996; Ramadan 1995).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with toxicity:</i> Serum azithromycin levels of ≥0.8 ± 0.4 mg/L have been associated with ototoxicity (Brown 1997).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961955"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Azee | Azi once | Aziglen | Azijub | Azithromax | Azomax | Azomycin | Azyter | Henacyl | Macromax | Mazit | Z Mycin | Zetron | Zithrocon | Zithromax</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Arzomicin | Azitral | Azitrin | Azitrogal | Azitrolabsa | Azitrolan | Azitromicina dupom | Azitromicina Hlb | Azitromicina nexo | Azitromicina northia | Azitromicina puntanos | Azitromicina richet | Azitrona klonal | Azitrox | Clearsing | Cronopen | Doyle | Fabodrox | Fabramicina | Fina | Izotrop | Macromax | Misultina | Mixoterin | Neblic | Nifostin | Novozitron | Orobiotic | Sitrox | Sumir | Talcilina | Tanezox | Trexbiotic | Triamid | Tritab Azydrop | Vectocilina | Zitromax</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Azistro | Azithromycin +Pharma | Azithromycin 1a pharma | Azithromycin Actavis | Azithromycin Arcana | Azithromycin Genericon | Azithromycin krka | Azithromycin ratiopharm | Azithromycin sandoz | Azithromycin stada | Azyter | Zithromax</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo azithromycin | Azith | Azithromycin aft | Azithromycin alphapharm | Azithromycin an | Azithromycin ga | Azithromycin maxrx | Azithromycin mylan | Azithromycin sandoz | Dbl azithromycin | Zedd | Zithro | Zithromax | Zitrocin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Accuzith | Acos | Adiz | Amzith | Arthromycin | Asizith | Avalon | Az | Azalid | Azaltic | Azasite | Azexia | Azicin | Azikil | Azilab | Azilit | Azimex | Azimon | Azin | Azinaaf | Azinil | Azitel | Azithin | Azithrocin | Azithromax | Azitra | Azix | Azo | Azocin | Azomac | Azosil | Azro | Azyth | Benzith | Cinalid | Curazith | Ezith | Fizyth | Hyzith | Ilozin | Macazi | Macrobac | Macrozith | Maczith | Makzit | Mazith | Myzid | Neozith | Novazith | Odaz | Odazyth | Orgazith | Penalox | Phagocin | Ranzith | Razithro | Respazit | Romycin | Rozith | SB Azit | Simpli 3 | Telide | Tridosil | Truzith | Tyzith | Verizith | Vinzam | Xolide | Zemycin | Zeocin | Zibac | Zimax | Zinex | Zita | Zithrin | Zithro | Zithrolex | Zithrox | Zitrex | Zixin | Zunami | Zycin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Azithromed | Azithromycin ab | Azithromycin Apotex | Azithromycine eurogenerics | Azithromycine mylan | Azithromycine sandoz | Azithromycine Sandoz | Azithromycine Teva | Zitromax</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Atmax | Aurothrin | Azibact | Azicure | Azifair | Azilide | Azimax | Azimo | Aziren | Aziron | Azithrin | Azithro | Azitrine | Azix | Azyter | Binozyt | Cronopen | Iz 500 | Rolicin | Unizithrin | Uzet | Vikthro | Zithromax</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Azatril | Azax | Azibiot | Azitrox | Azyter | Binozyt | Sumamed | Zethrum | Zmax</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Astro | Astro iv | Atromicin | Azalide | Azi | Azicin | Azidromic | Azimax | Azimed | Azimix | Azinostil | Azitrax | Azitrin | Azitrocin | Azitrocina | Azitrogran | Azitrolab | Azitromed | Azitromicil | Azitromicina | Azitromicina di hidratada | Azitromicina diidratada | Azitromicina monoidratada | Azitromin | Azitron | Azitronax | Azitrophar | Azitrosol | Azitroxil | Azomicin | Biozitrom | Clindal az | Novatrex | Selimax | Siftromin | Teutrazi | Tevazi | Tromix | Tromizir | Zimicina | Zirk | Zitrac | Zitrina | Zitrobiol | Zitromax | Zitromil | Zitroneo | Zolprox</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Azithromycin mepha | Azithromycin pfizer | Azithromycin sandoz | Azithromycin Sandoz Eco | Azithromycin Spirig | Zithromax</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">A-cin | Apexime | Atmax | Azee | Azicure | Azient | Azilide | Azimo | Azipar | Aziron | Azithrin | Azithro | Azithromycin mepha | Azitro | Azix | Azro | Azyter | Binozyt | Cronopen | Iz 200 | Iz 500 | Largithrome | Lyzit | Rolicin | Shalzin | Smegaz | Swilide | Thromiz | Unozit | Vikthro | Zimax | Zimytron | Zith | Zithromax | Zithrotil | Zocin | Zomax</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Abacten | Asipral | Atizor | Azalid | Azibay | Azibiotic | Azimit | Azithral | Azitrom | Azitromicina | Azydrop | Dinamicina | Ricilina | Trex | Zetamax | Zithromax</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">A mei qi | A sai qi | Ai mi qi | Ai mo yan zhi | An mei qin | Ao li ping | Ao qi xing | Azithromycin and glucose | Azithromycin and sodium chloride | Azithromycin dihydrochloride | Azithromycin granules (ii) | Bai ke de rui | Bin ji | Bin qi | Bo kang | Chen yu | Feng da qi | Fu qi | Fu qi xing | Hao qi | Hua xi | Ji hong | Ji long mai | Jia yao | Jin bo | Jin duo qi | Jin pai qi | Jun jie | Kai qi | Kang li jian | Ke lin da | Li ke si | Li li xin | Li pu xin | Li qi | Lin bi | Lou gu kang | Luoxin kuai yu | Ming qi xin | Na qi | Pai fu | Pu le qi | Qi hong | Qi long mai | Qi nuo | Qi xian | Rich | Rui qi | Rui qi lin | Sai qi | Shu luo kang | Shu yan te | Shun feng kang qi | Shunfeng kang qi | Sumamed | Tai li te | Te li xin | Tianlong xin zhi | Tuo neng | Wei hong | Wei lu de | Xi mei | Xin pi te | Xin pu rui | Ya si da | Yi ou qing | Yi qi su | Yi song | Yi xin | Yin pei kang | You ni ke | Yuan da xing | Zai qi | Ze qi | Zithromax</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Akribact | Albaczitrol | Albazitrom | Alenat | Amepril | Angifal | Atromed | Atromizin | Auroalzyl | Azibay | Azibiotrim | Azifast | Azimin | Azinobin | Azitiv | Azitrobac | Azitrofar | Azitrogram | Azitromicina | Azitromicina mk | Azkar | Azomax | Aztrobac | Azybactrol | Azydrop | Bactrosafe | Bacty bx | Bakzia | Binozyt | Bitrozil | Cronozit | Exu3max | Fonkink | Impofin z | Koptin | Kromicin | Macrozit | Maxtre | Milagram | Natrozim | Orazit | Penfluz | Prosfin | Rantiz | Tobil | Tromazin | Tromipen | Tromix | Tromix SD | Zaret | Zidoxtifen | Zimericina | Zithrocin | Zitrim | Zitroflan | Zitromax | Zitrosher</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo azithromycin | Azibiot | Azibiot neo | Azithromycin Actavis | Azithromycin aurovitas | Azithromycin IC Pharmacon | Azithromycin ratiopharm | Azitromicina | Azitromycin Mylan | Azitrox | Azyter | Sumamed | Trozamil | Zetamac | Zitrocin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Azi | Azithro Meda | Azithromycin 1A Pharma | Azithromycin Aristo | Azithromycin denk | Azithromycin eberth | Azithromycin hec | Azithromycin Heumann | Azithromycin hexal | Azithromycin orifarm | Azithromycin ratiopharm | Azithromycin stada | Infectoazit | Ultreon | Zithromax | Zitromax</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Azithromycin 1a farma | Azithromycin hexal</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Aruzilina | Arzomicin | Atm | Azibiotic | Azicip | Azicure | Azilide | Azinfec | Azitrobac | Azitrofel | Azitrom | Azitromicina | Azitromicina Calox | Azitromicina lam | Azitromicina mamey | Azitromicina mk | Azthomac | Bactazit | Bactexina | Binozyt | Clazit | Cletsin | Faxin | Fuscata DA | Imbys | Koptin | Lutromicin | Macrozit | Magnabiotic | Nor-Zimax | Pediagesic | Tobil | Trex | Trex forte | Tromic | Udox | Vectocilina | Xitrox | Zaret | Zithromax | Zitrix | Zitrobac | Zitrocaps | Zitrocyn | Zitromax MD | Zostrix</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">3 micina | Acibacter | Arzomicin | Avsoir | Azee | Azetatrix | Azibay | Aziffel | Aziletic | Aziquilab | Azistar | Azitrex | Azitril | Azitrobac | Azitrocher | Azitrom | Azitromicina | Azitromicina mk | Azitromin | Azitron | Azitrosa | Azitrowin | Azmicina | Binozyt | Biomicyn | Epica | Erdam | Erdam f | Etrozit | Geozit | Locxus t | Nokar | Nurox | Ricilina | Tobil | Trex | Tri azit | Ultrabac | Xitrom | Zimericina | Zimycin | Zitric | Zitromax | Zitrox</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Azimepha | Azithromycin grindeks | Azithromycin krka | Azitrox | Sumamed | Zedbac | Zitraval | Zylumit</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Azalide | Azatribact | Azi once | Azindamon | Aziraz | Azirowa | Azitanad | Azithroglob | Azithromash | Aziwok | Azomycin | Azrolid | Delzosin | Epizithro | Glozithro | Infectomycin | Neozolid | Rame Zithro | Unizithrin | Unizithrocure | Xerexomair | Xithrone | Zathrotrue | Zisrocin | Zithrodose | Zithrokan | Zithromax | Zithroriv | Zmax | Zmaxe</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Aratro | Azitromicina | Azitromicina actavis | Azitromicina almus | Azitromicina altan | Azitromicina Alter | Azitromicina apotex | Azitromicina aristo | Azitromicina bayvit | Azitromicina bexal | Azitromicina bluepharma | Azitromicina cinfa | Azitromicina Combix | Azitromicina Cuve | Azitromicina davur | Azitromicina fimol | Azitromicina Ges Genericos | Azitromicina juventus | Azitromicina Kern | Azitromicina krka | Azitromicina mabo | Azitromicina merck | Azitromicina Pensa | Azitromicina pharmacia | Azitromicina pharmagenus | Azitromicina pharmgenus | Azitromicina Qualigen | Azitromicina Ranbaxy | Azitromicina ratiopharm | Azitromicina rubio | Azitromicina sandoz | Azitromicina tarbis | Azitromicina tecnimede | Azitromicina Teva | Azitromicina ur | Azitromicina vir | Azitromicina Winthrop | Azydrop | Goxil | Toraseptol | Vinzam | Zentavion | Zitromax</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Azaltic | Azi once | Azibial | Azibru | Azin | Azirox | Azithromicin | Azithromycin | Azovid | Binozyt | Z Mycin | Zathrin | Zilacid | Ziomycin | Zithromax | Zithroriv</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Amzolynic | Azithromycin hexal | Azithromycin krka | Azithromycin merck | Azithromycin mylan | Azithromycin Orion | Azithromycin ratiopharm | Azithromycin sandoz | Azithromycin stada | Azithromycin teva | Azyter | Zithromax</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Azadose | Azithromycine almus | Azithromycine Arrow | Azithromycine biogaran | Azithromycine Cristers | Azithromycine EG | Azithromycine evolugen | Azithromycine krka | Azithromycine phr lab | Azithromycine qualimed | Azithromycine Ranbaxy | Azithromycine ratiopharm | Azithromycine sandoz | Azithromycine Winthrop | Azithromycine Zydus | Azyter | Zithromax</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Aziglobe | Azithromycin | Azyter | Clamelle | Zithromax</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Alive azithro</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Azirox | Azirutec | Azithrin | Azithromycin/Generics | Azithromycin/Teva | Azithromycin/Vocat | Azitrolid | Azivirus | Azyter | Bezanin | Ciroz | Figothrom | Goldamycin | Gramokil | Novozithron | Razimax | Thoraxx | Zinfect | Zithro-Due | Zithrobest | Zithromax | Zithroplus | Zithrotel | Zithroxyn | Zitrax/Genepharm</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo azithromycin | Apo azithromycin z | Azibact | Azimax | Azin | Azinix | Azirodin | Azithmax | Azithrocin | Azyter | Binozyt | Clindal az | Imexa | Nifomax | Vick azithro | Zathrin | Zimax | Zithromax | Zmax | Zotax</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Azibiot | Azimed | Azitrim | Azitromicin | Azitromicin Belupo | Azitromicin Genera | Azitromicin Lek | Azitromicin PharmaS | Azitromicin Sandoz | Azitromicin Sandoz forte | Azyter | Makromicin | Sumamed | Sumamed 1200 | Sumamed forte</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Azi | Azi sandoz | Azibiot | Azirowill | Azithromycin 1 A Pharma | Azithromycin aramis | Azithromycin ratiopharm | Azithromycin sandoz | Aziwill | Makromycin | Sumamed | Zitinn | Zitrocin | Zmax</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Azivol | Aziwin | Azomax | Azomep | Aztercon | Aztrin | Azyter | Binozyt | Ethrimax | Ethrimax ds | Iztron | Maxmor | Mezatrin | Trozin | Zarom | Zibramax | Zicho | Zistic | Zithrax | Zithrolic | Zithromax | Zitrolin | Zycin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Azithromycin krka | Azromax | Azyter | Zithromax | Zithromel</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Azenil | Zeto</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ab | Actimycin | Agee | Akomin | Aliza | Amithro | Aqthral | Arl azi | Arrow | Asitomycin | Atm | Atral | Atryn | Avindo | Avnext | Axicin | Azad | Azag | Azam | Azard | Azax | Azcre | Azee | Azeemune | Azegud | Azemine | Azenas | Azest | Azex | Azforin | Azi big | Aziagio | Azibact | Azibest | Aziblue | Azibond | Azibrawn | Azicare | Azicin | Azicip | Aziclass | Azicom | Azicrat | Azicure | Azicyte | Azid | Azidac | Aziday | Azidep | Azidon | Azidoz | Azifast | Azifine | Azifine + | Aziforce | Azigard | Azigem | Azikam | Azikap | Azikare | Azikem | Azil | Azileb | Azilet | Aziley | Azilide | Azilin | Aziliz | Azilup | Azimac | Azimacro | Azimax | Azimer | Azimic | Azimist | Azimon | Azimount | Azimy | Azina | Azindica | Azinij | Azinix | Azinol | Azinova | Azipar | Azipen | Aziphar | Azipos | Azipro | Aziquest | Azirapid | Azirav | Aziresp | Azirin | Azirite | Azirom | Azis | Azisa | Azisam | Azisara | Azistart | Azistatic | Aziswift | Azitack | Azitas | Azitaz | Azitec | Azitech | Aziter | Azitest | Azitex | Azith | Azithral | Azithral 5d | Azithral-Si | Azithree | Azithro | Azithrox | Azitis | Azitive | Azito | Azitol | Azitop | Azitrac | Azitrix | Azitroy | Azitru | Azitsa | Azitus | Aziva | Azivista | Azivo | Aziwin | Aziwis | Aziwok | Azlin | Azlupin | Azni | Azo | Azocin | Azom | Azomarc | Azomax | Azoo | Azorit | Azorta | Azosern | Azotik | Azotox | Azoxyn | Azrade | Azro | Azuda | Azuma | Azy | Azya | Azylaj | Azyric | Azyrise | Azysafe | Azyxin | Azza | Cazithro | Cithro | Covaz | Direkt | Dizithro | Doxy-1-up | Ecothral | Elderaze | Elgram | Elzee | Exthro | Ezecure | Finocin | Flaag | Forit | Gerimic | Gerithro | Ibithral | Izamed | Izicin | Izzi | Kamzi | Lariza | Laz | Litazith | Loromycin | Macroazi | Macrosafe | Macrotor | Macrozac | Maxithral | Mazith | Mazithro | Megamac | Meraz | Microbact | Miomycin | Myaz | Nazith | Nuazy | Onazit | Ortiza | Osmozyth | Oxzyth | Ozicin | Ozitop | Ozorox | Plugcin | Pratham | Prazith | Pulmo azi | Q Azi | Qurazit | Ralistar | Retramycin | Ribonyl | Ronin | Rulide AZ | Russ | Sarzi | Savazee | Sazith | Servazith | Skomyce | Somycin | Sp azy | Stanmycin a | Stazee | Suprazi | Swithro | Systhral | Tazit | Tazix | Tecazi | Trulimax | Uthral | Uzazy | Valuethral | Vazir | Ventrox DS | Veriaz | Verzit | Vicon | Xith | Xithro | Yashzi | Z 1 | Zady | Zaha | Zanthocin | Zarocin | Zathrin | Zeethrom | Zenmac | Zetorin | Zicin | Ziethem | Zigaf | Ziox | Zithium | Zithree | Zithrobact | Zithrocare | Zithrocin | Zithrolect | Zithrox | Ziticin | Ziwal | Zofacin | Zohri | Zoom | Zorpido | Zycin | Zylid</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Awazitro | Azithromycin | Azithromycin mdi | Azithrosam | Jazithrocin | Zithro once</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Azacid | Azeptin | Azitredil | Azitrocin | Azitroerre | Azitromicina | Azitromicina actavis | Azitromicina almus | Azitromicina Doc | Azitromicina EG | Azitromicina Fg | Azitromicina Germed | Azitromicina krka | Azitromicina Myl | Azitromicina mylan | Azitromicina proge farm | Azitromicina sandoz gmbh | Azitromicina wpi | Azitrox | Azylung | Azyter | Batif | Cinetrin | Macrozit | Nemezid | Portex | Rezan | Ribotrex | Tetris | Trimelin | Trozamil | Trozocina | Zimacrol | Zindel | Zitrobiotic | Zitrogram | Zitromax | Zitromax Avium | Zitroneg</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Azi once | Azicure | Azitam | Azomycin | Azomyne | Zaha | Zeeto | Zimax | Zithromax | Zomax | Zoro</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Azithromycin kog | Azithromycin sandoz | Azithromycin teva | Zithromac | Zmax</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Agycin | Atm | Azal | Azaltic | Azbact | Azi bio | Aziagio | Azibru | Azic | Azicen | Azicin | Azicip | Azicure | Azidawa | Azidoc | Azifast | Azifred | Azifred ds | Azik | Azileb | Azilide | Azilin | Azimac | Azimax | Azimed | Azimet | Azimol | Azin | Azines | Azinowel | Azipar | Azique | Azita | Azitcor | Azitec | Azithraa | Azithral | Azithrax | Azithrax pfs | Azithrin | Azithrocin | Azithrosafe | Azito | Azitro | Aziwin | Aziwok | Azix | Azo | Azomac | Azox | Azuma | Azy | Binozyt | Conzit | Enaz | Macrolyn | Macrosafe | Maczith | Markaz | Mazit | Odazyth sr | Ortiza | Plazo | Romycin | Rozith | Sazro | Shalzin | Stanzi | Swazi | Threomycin | Thromiz | Throza | Throza dps | Unozit | Xolide | Zadiways | Zaha | Zathrin | Zerocin | Zetro | Zibac | Zicith | Zimax | Zimycin | Zithrocare | Zithrocin | Zithrolite | Zithromax | Zithroriv | Zithrox | Zitro | Zmax | Zocin | Zomax | Ztm | Zymcin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ajustin | Alvogen azithromycin | Asmaxin | Athmaxin | Azath | Azeto | Azi v | Azimax | Azirocin | Aziromax | Azithra | Azithrin | Azithromycin daewoong | Azithromycin dwn | Azithron | Azitops | Azitron | Binozyt | Daehwa azithromycin | Daewoong azithromycin | Macromax | Ql azithromycin | Samnam azisromysin | Withus azithromycin | Yungjin azithromycin | Zentas | Zidmax | Ziromex | Zithromax | Zithromin | Zitrocin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Azi once | Azimac | Azomycin | Azyter | Macromax | Xithrone | Zetron | Zimax | Zithromax</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Azicin | Azicure | Azifast | Azimax | Azitam | Azm 500 | Azomycin | Azomyne | Azyter | Hemomycin | Zetron | Zevlen | Zithroforte | Zithromax | Zithroplus</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Azibiot | Azimepha | Azithromycin Actavis | Azithromycin grindeks | Azithromycin ingen | Azitromycine sandoz | Azitrox | Azyter | Infectoazit | Sumamed | Zmax | Zylumit</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Azithromycin hexal | Azithromycin ratiopharm | Azithromycine EG | Azyter | Zitromax</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Azibiot | Azimepha | Azithromycin Actavis | Azithromycin grindeks | Azithromycin krka | Sumamed | Zithromax | Zitraval</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Az | Azibac | Azilide | Azimax | Azithrix | Azithromycine Winthrop | Azix | Azyter | Macromax | Mazax | Unizitro | Zithromax</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aclarium | Amizt sr | Atoxitom | Azgorfin | Azibiot | Azidral | Aziphar | Azitrocin | Azitrocin g | Azitrocin md | Azitrohexal | Azitromicin | Azitromicina | Azitromicina Alpharma | Azitromicina gi se | Azitromicina Loeffler | Azitromicina Raam | Azo Max | Azotive | Aztrogecin | Charyn | Craztronin | Koptin | Macrofag | Macrozit | Marzivag | Mizotryn | Samitrogen | Sicalan | Texis | Tromicina | Truxa | Vectrizan | Zertalin | Zinotram | Zitroken | Zyter</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Axcel azithromycin | Azee | Azimax | Aziswift | Azithral | Azithromycin hec | Azyter | Azytro | Binozyt | Hp azithromycin | Imexa | Kidimac | Unimed's azithral | Vaxcel azithromycin | Ziomycin | Zithrolide | Zithromax | Zithronam | Zmax | Zynomax</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Aions azithromycin | Amphomul | Azifam | Azigraf | Azisure | Azitam | Azithromycin | Azuma | Cetroxol | Danthromycin | Errdon azithromycin | Gremax | Gudomycin | Hanzithro | Johnbee azithromycin | Justeen azithromycin | Kasifa | Lysomax | Macrosafe | Mayglow azithromycin | Myzith | Nobaxin | Poccozith | Pythrocin | Qualihealth azithromycin | Razitro | Shalzin | Suitrox | Thromaxillin | Triaz | Viskomycin | Vitafan | Xith | Zetro | Zithroheal | Zithrokids | Zithropark | Zithroriv</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Azitromycine | Azitromycine actavis | Azitromycine CF | Azitromycine Merck | Azitromycine PCH | Azitromycine sandoz | Azyter | Zithromax</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Amzolynic | Azithromycin 1a pharma | Azithromycin Apotex | Azithromycin eberth | Azithromycin hexal | Azithromycin life | Azithromycin qualigen | Azithromycin teva | Azitromax | Azitromicina altan Macure | Azyter | Zedbac | Zithromax | Zitromax</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo azithromycin | Arrow Azithromycin | Zithromax</span>;</li>
<li>
<span class="countryCode">(PA)</span> <span class="country">Panama</span><span class="countrySeparator">: </span><span class="drugName">Azitropan</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">3dt biotic | Abacten | Amixef | Astidal | Astrocina | Atizor | Azbact | Azibay | Azibrand | Azicat | Azifar | Azilide | Azilin | Azimut | Aziquilab | Azitor | Azitral | Azitrolit | Azitromac | Azitromicina | Azitropharma | Azonacaf | Azycov | Azynor | Belsuc | Binozyt | Bruclav s | Elazit | Inedol | Iramicina | Lefren | Macrozit | Ricilina | Setron | Trex | Tri azit | Trimax | Trimox | Vazimass | Viquezit | Xalitrox | Z 3 | Zipack | Zirax | Zitax | Zithrosun | Zithrotil | Zitomina | Zitrax | Zitriex | Zitrobac | Zitrobiot | Zitrocom | Zitrofar | Zitrofor | Zitrogal | Zitrolab | Zitromax | Zitrophar | Zitrosedyl forte | Zitrotrim | Zitrozin | Zitylor</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Anzal | Athrodim | Aza | Azal | Azeecor | Azeemycin | Azemax | Azent | Azi | Aziguard | Azihold | Azik | Azilife | Azimax | Azimin | Aziprime | Aziro | Azithro | Azithromycin Winthrop | Azitrocin | Azo | Azomac | Aztor | Aztro | Azyth | Berzimax | Biomac | Cinazith | Cinazith ds | Cytrazi | Dafzith | Decantin | Enaz | Enaz ds | Ezythromax | Gozimax | Mykmaxin | Od mac | Pediazith | Rhea azithromycin | Rifethromycin | S Troz | Sitimax | Thromaxin | Trozin | Wiltrozin | Zenith | Zit od | Zithrobbas | Zithrocare | Zithrocin | Zithromax | Zithrozan</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">A mycin | Acasia | Aezit | Ajicin | Alide | Altezyme | Alzacin | Apocine | Arsomycin | Arzomic | Aspracin | Athofix | Atizor | Azaltic | Azecid | Azeloc | Azi once | Azibect | Azicob | Azicure | Azidose | Azigold | Azikem | Azikit | Azilite | Aziloride | Azimal | Azimic | Azimycin | Azineu | Azinor | Azintra | Azipos | Azirol | Azirolide | Azisia | Azisoft | Azista | Azit | Azitab | Azitek | Azith | Azithrocin | Azithrolide | Azithronext | Azithrotab | Azitin | Azitma | Azitron | Azo | Azobit | Azocam | Azocam ds | Azocin | Azogil | Azoheim | Azomax | Azomexin | Azomont | Azonic | Azopik | Azoreg | Azores | Azorox | Azot | Azotek | Azour | Azovic | Azoxin | Azpar | Azrocin | Aztrix | Azure | Azydec | Azythra | Bactizith | Biozith | Cararox | Cibacin | Cyzit | D kortes | Delide | Dv zythro | Ezimax | Ezonex | G azithro | Genthro | Geozit | I zit | Indaz | Infazith | Jazonak | Jutromes | Kadura | Kinlec | Kinra | Kraze | Macrobac | Macrocap | Macrowin | Macrozith | Maczin | Mapzit | Maxithro | Megatab | Mezethro | Mynex | Navozith | Onznex | Palthro | Plazo | Plivazith | Prizocin | Ram off | Ramacin | Rayaz | Renzith | Resque | Romycin | Rothin | Rozorox | Servaz | Spell | Thiaza | Thiza | Throb | Trazacin | Trezo | Triazit | Tweet | Wenozith | Winkmycin | Z cin | Z-Mac | Zabio | Zady | Zaracin | Zee | Zeecin | Zelinz | Zenados | Zesty | Zetamax | Zetro | Zezot | Zibac | Zicure | Zidor | Zimax | Zitamed | Zithben | Zithin | Zithosim | Zithrocin | Zithrolide | Zithromax | Zithromed | Zithrosan | Zithrox | Zitpro | Zitro | Zolecta | Zomax | Zorix | Zyask | Zycin | Zygrel | Zyto</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Azibiot | Azigen | Azimycin | Aziteva | Azithromycin 1 A Pharma | Azithromycin advisors | Azithromycin aurovitas | Azithromycin eberth | Azithromycin krka | Azithromycin ratiopharm | Azitrin | Azitro | Azitrogen | Azitrolek | Azitrox | Azix | Azycyna | Azytact | Azyter | Bactrazol | Canbiox | Macromax | Nobaxin | Oranex | Sumamed | Zetamax</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Azithromycin | Zithromax | Zithromax Tri-Pak | Zithromax Z-Pak | Zmax</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">3z | Azimed | Azitrix | Azitromicin Parke-Davis | Azitromicina | Azitromicina 3z | Azitromicina actavis | Azitromicina almus | Azitromicina azevedos | Azitromicina basi | Azitromicina krka | Azitromicina mylan | Azitromicina pentafarma | Azitromicina Ranbaxy | Azitromicina wynn | Azyter | Gigatrom | Neofarmiz | Unizitro | Zithromax</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Actizim | Amizin | Aruzilina | Atrimon | Azimut | Azitroland | Azitromicina bilac | Azitromicina cellofarm | Azitromicina dallas | Azitromicina dutriec | Azitromicina eurofarma | Azitromicina fda | Azitromicina icu vita | Azitromicina imedic | Azitromicina millet | Azitromicina p.a.n | Azitromicina phi | Azitromicina polimed | Azitromicina promepar | Azitromicina prosalud | Azitromicina synmedic | Azitronest | Azitropen | Clearsing | Erimax | Hecomicina | Klizin | Koptin | Nifostin | Nurox | Nurox forte | Ricilina | Trex | Trex forte | Triam | Tribron | Tritab</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Azeltin | AZi-Once | Azomycin | Azomyne | Macromax | Mazit | Qzit | Zeecin | Zetron | Zimax | Zithromax | Zithrova | Zocin | Zomax</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Azatril | Azibiot | Azitromicina arena | Azitromicina aurobindo | Azitromicina Sandoz | Azitromicina terapia | Azitrox | Azro | Azyter | Sumamed forte | Zitrocin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Azibiot | Azicid | Azidrop | Azimycin | Azithromycin | Azithromycin ecomed | Azithromycin forte | Azithromycin j | Azithromycin macleods | Azithromycin sandoz | Azithromycin sanofi | Azithromycin zentiva | Azithrus | Azitrox | Azitrus | Azitrus forte | Ecomed | Hemomycin | Suitrox | Sumaclid | Sumamecin forte | Sumamed | Sumamed forte | Sumamox | Tremak Sanovel | Zetamax | Zi factor | Zimax | Ziromin | Zithrocin | Zithromycin | Zitnob | Zitrocin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Azi once | Azimac | Azolid | Azomycin | Azomyne | Azyter | Zerox | Zetron | Zimax | Zithromax | Zomax</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Azithrocare | Azithromycin 2care4 | Azithromycin Actavis | Azithromycin bijon | Azithromycin krka | Azithromycin mylan | Azithromycin orifarm | Azithromycin sandoz | Azithromycin stada | Azitromax | Azitromycin ebb | Azyter</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo azithromycin | Azimax | Azmycin | Binozyt | Imexa | Zithromax | Zmax</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Azibiot | Sumamed | Zigilex | Zitrocin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Azithromycin Actavis | Azithromycin krka | Azithromycin sandoz | Azitromycin Mylan | Azitrox | Sumamed | Zigilex | Zitrocin | Zmax</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Agycin | Xithro</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Azith | Azyter | Floctil | Manazith | Onzet | Zithromax | Zithrotel | Zmax</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Azacine | Azitral | Azitromin duo | Azitromin trio | Azix | Azro | Azyter | Trimax | Zithrocare | Zithromax | Zitro | Zocin | Zomax</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Azacid | Azeltin | Azitro | Azitrotek | Azomax | Azro | Azyter | Tremac | Ziromin | Zitromax | Zitrotek</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ansumycin | Aziciin | Azithrom | Azithromycin sandoz | Rosucin | Zirocin | Zithromax | Zythrocin</span>;</li>
<li>
<span class="countryCode">(TZ)</span> <span class="country">Tanzania, United Republic of</span><span class="countrySeparator">: </span><span class="drugName">Azuma</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Azax | Aziagio | Azibiot | Azicin | Azimed | Azinort | Azioptic Romfarm | Azipol | Azithral | Azithro | Azithrohexal | Azithrom | Azithromax | Azithromycin euro | Azithromycin grindeks | Azithromycin ratiopharm | Azithromycinum 250 | Aziwok | Aztek | Azyter | Hemomycin | Mitrozyd | Ormax | Sumamed | Sumamed forte | Zetamax | Zibax | Ziromin | Zithrocin | Zitrox | Zoxy</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agycin | Az | Azaltic | Azee | Aziagio | Aziberg | Azibru | Azicin | Azicure | Azifam | Azifast | Azileb | Azilide | Azilin | Azinowel | Aziriv | Azithraa | Azithrocin | Azito | Azitro | Azomycin | Azy | Azzy | Binozyt | Cazithro | Macrolyn | Romycin | Swazi | Xithrone | Zaha | Zathrin | Zeecin | Zimax | Zimexir | Zimycin | Zithrocin | Zithromax | Zithroriv | Zithrox | Zocin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Alin | Arzomicin | Astro | Azicu | Azitrom | Azitromicina | Azitromicina Donier | Azitromicina phs | Campozin | Sitrox | Trex | Zitromax</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Amizin | Amovin | Aruzilina | Arzomidol | Atromizin | Az trobac | Azeewell | Azigram | Azimakrol | Azitrodex | Azitromicina | Azitromin | Azitromin-g | Binozyt | Cronopen | Imbys | Impofin z | Macrosafe | Odazyth | Saver | Trozimid | Xitrox | Zimax | Zitromax | Zival | Zocin</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Agitro | Azicrom | Azieurolife | Azilyo | Becazithro | Cadiazith | Doromax | Fabazixin | Frazix | Garosi | Maxazith | Mulasmin | Myeromax | Opeatrop | Synazithral | Zaromax</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aspen Azithromycin | Austell Azithromycin | Azero | Azithromycin biotech | Azithromycin sandoz | Azithromycin strides | Azithromycin unicorn | Azrasite | Binozyt | Cipla azithromycin | Jubazi | Medpro Azithromycin | Novazith | Ultreon | Zathrin | Zithrocin | Zithromax | Zydus azithromycin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Agycin | Az-1 | Azi bio | Azicure | Azifast | Azileb | Azith | Azithral | Azitrine | Azuma | Shalzin | Throza | Zaha | Zimax | Zithrocare | Zithromax | Zithrox | Zycin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Sky pharm azithromycin | Zithromax | Zmax</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27832694">
<a name="27832694"></a>Abtahi H, Peiman S, Foroumandi M, Safavi E. Long term follow-up of sulfur mustard related bronchiolitis obliterans treatment. <i>Acta Med Iran</i>. 2016;54(9):605-609.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/27832694/pubmed" id="27832694" target="_blank">27832694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14557959">
<a name="14557959"></a>Adachi JA, Ericsson CD, Jiang ZD, et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. <i>Clin Infect Dis</i>. 2003;37(9):1165-1171. doi:10.1086/378746<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/14557959/pubmed" id="14557959" target="_blank">14557959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Agha.2018">
<a name="Agha.2018"></a>Agha R, Goldberg MB. Shigella infection: treatment and prevention in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21864166">
<a name="21864166"></a>Albert RK, Connett J, Bailey WC, et al; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD [published correction appears in <i>N Engl J Med. </i>2012;366(14):1356]. <i>N Engl J Med</i>. 2011;365(8):689-698.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/21864166/pubmed" id="21864166" target="_blank">21864166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25558301">
<a name="25558301"></a>Almalki ZS, Guo JJ. Cardiovascular events and safety outcomes associated with azithromycin therapy: a meta-analysis of randomized controlled trials. <i>Am Health Drug Benefits</i>. 2014;7(6):318-328.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25558301/pubmed" id="25558301" target="_blank">25558301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23532241">
<a name="23532241"></a>Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. <i>JAMA</i>. 2013;309(12):1251-1259. doi: 10.1001/jama.2013.1937.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/23532241/pubmed" id="23532241" target="_blank">23532241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23812485">
<a name="23812485"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 135: Second-trimester abortion. <i>Obstet Gynecol</i>. 2013;121(6):1394-1406. doi:10.1097/01.AOG.0000431056.79334.cc<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/23812485/pubmed" id="23812485" target="_blank">23812485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29794678">
<a name="29794678"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin No. 195: Prevention of infection after gynecologic procedures. <i>Obstet Gynecol</i>. 2018a;131(6):e172-e189. doi:10.1097/AOG.0000000000002670<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/30134425/pubmed" id="30134425" target="_blank">30134425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30134425">
<a name="30134425"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 199: Use of prophylactic antibiotics in labor and delivery. <i>Obstet Gynecol</i>. 2018b;132(3):e103-e119. doi: 10.1097/AOG.0000000000002833.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/30134425/pubmed" id="30134425" target="_blank">30134425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32080050">
<a name="32080050"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 217: Prelabor rupture of membranes. <i>Obstet Gynecol</i>. 2020;135(3):e80-e97. doi:10.1097/AOG.0000000000003700<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/32080050/pubmed" id="32080050" target="_blank">32080050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15127872">
<a name="15127872"></a>American Dental Association Council on Scientific Affairs. Combating Antibiotic Resistance. <i>J Am Dent Assoc</i>. 2004;135(4):484-487.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/15127872/pubmed" id="15127872" target="_blank">15127872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9869584">
<a name="9869584"></a>Amsden GW, Nafziger AN, Foulds G. Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects. <i>Antimicrob Agents Chemother</i>. 1999;43(1):163-165.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/9869584/pubmed" id="9869584" target="_blank">9869584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28726337">
<a name="28726337"></a>An I, Demir V, Akdeniz S. Fixed drug eruption probably induced by azithromycin. <i>Australas J Dermatol</i>. 2017;58(4):e253-e254. doi:10.1111/ajd.12563<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/28726337/pubmed" id="28726337" target="_blank">28726337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33568349">
<a name="33568349"></a>Andersson NW, Olsen RH, Andersen JT. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study. <i>BMJ</i>. 2021;372:n107. doi:10.1136/bmj.n107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/33568349/pubmed" id="33568349" target="_blank">33568349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30913334">
<a name="30913334"></a>Angarone M, Snydman DR; AST ID Community of Practice. Diagnosis and management of diarrhea in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13550. doi:10.1111/ctr.13550<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/30913334/pubmed" id="30913334" target="_blank">30913334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18991703">
<a name="18991703"></a>Araújo L, Demoly P. Macrolides allergy. <i>Curr Pharm Des</i>. 2008;14(27):2840-2862. doi:10.2174/138161208786369812<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/18991703/pubmed" id="18991703" target="_blank">18991703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11459586">
<a name="11459586"></a>Arellano-Rodrigo E, García A, Mont L, Roqué M. Torsade de pointes y parada cardiorrespiratoria inducida por azitromicina en una paciente con síndrome de QT largo congénito [Torsade de pointes and cardiorespiratory arrest induced by azithromycin in a patient with congenital long QT syndrome]. Article in Spanish. <i>Med Clin (Barc)</i>. 2001;117(3):118-119. doi:10.1016/s0025-7753(01)72036-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/11459586/pubmed" id="11459586" target="_blank">11459586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. American College of Physicians; 2007:58, 151.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14506028">
<a name="14506028"></a>Arrieta A, Arguedas A, Fernandez P, et al. High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media. <i>Antimicrob Agents Chemother</i>. 2003;47(10):3179-3186. doi:10.1128/AAC.47.10.3179-3186.2003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/14506028/pubmed" id="14506028" target="_blank">14506028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Slate.1">
<a name="Slate.1"></a>Azithromycin injection [prescribing information]. Columbus, OH: Slate Run Pharmaceuticals; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva.1">
<a name="Teva.1"></a>Azithromycin monohydrate powder [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; September 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lupin.1">
<a name="Lupin.1"></a>Azithromycin suspension [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Epic.1">
<a name="Epic.1"></a>Azithromycin suspension [prescribing information]. Laurelton, NY: Epic Pharma, LLC; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandoz.1">
<a name="Sandoz.1"></a>Azithromycin suspension [eMC summary of product characteristics]. Camberley, Surrey, United Kingdom: Sandoz Limited; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20666686">
<a name="20666686"></a>Babaeinejad S, Khodaeiani E, Fouladi RF. Comparison of therapeutic effects of oral doxycycline and azithromycin in patients with moderate acne vulgaris: What is the role of age? <i>J Dermatolog Treat</i>. 2011;22(4):206-210. doi:10.3109/09546631003762639<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/20666686/pubmed" id="20666686" target="_blank">20666686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bachmann.2018">
<a name="Bachmann.2018"></a>Bachmann LH. Urethritis in adult men. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17420199">
<a name="17420199"></a>Baker WL, Couch KA. Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis. <i>Am J Health Syst Pharm</i>. 2007;64(8):830-836. doi:10.2146/ajhp060539<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/17420199/pubmed" id="17420199" target="_blank">17420199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17550598">
<a name="17550598"></a>Ballard HO, Anstead MI, Shook LA. Azithromycin in the Extremely Low Birth Weight Infant for the Prevention of Bronchopulmonary Dysplasia: A Pilot Study. <i>Respir Res</i>. 2007;8:41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/17550598/pubmed" id="17550598" target="_blank">17550598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association (AHA). <i>Circulation</i>. 2015;132(15):1487-1515.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25302218">
<a name="25302218"></a>Banerjee I, Mondal S, Sen S, Tripathi SK, Banerjee G. Azithromycin-induced rash in a patient of infectious mononucleosis - a case report with review of literature. <i>J Clin Diagn Res</i>. 2014;8(8):HD01-HD2. doi:10.7860/JCDR/2014/9865.4729<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25302218/pubmed" id="25302218" target="_blank">25302218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barker.2018">
<a name="Barker.2018"></a>Barker AF. Bronchiectasis in adults: maintaining lung health. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 4, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25997306">
<a name="25997306"></a>Barni S, Butti D, Mori F, et al. Azithromycin is more allergenic than clarithromycin in children with suspected hypersensitivity reaction to macrolides. <i>J Investig Allergol Clin Immunol</i>. 2015;25(2):128-132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25997306/pubmed" id="25997306" target="_blank">25997306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9655532">
<a name="9655532"></a>Bass JW, Freitas BC, Freitas AD, et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for the treatment of cat-scratch disease. <i>Pediatr Infect Dis J.</i> 1998;17(6):447-452.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/9655532/pubmed" id="9655532" target="_blank">9655532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12712971">
<a name="12712971"></a>Basualdo W, Arbo A. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. <i>Pediatr Infect Dis J</i>. 2003;22(4):374-377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/12712971/pubmed" id="12712971" target="_blank">12712971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8557398">
<a name="8557398"></a>Bauernfeind A, Jungwirth R, Eberlein E. Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens. <i>Infection</i>. 1995;23(5):316-321. doi:10.1007/BF01716300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/8557398/pubmed" id="8557398" target="_blank">8557398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28787506">
<a name="28787506"></a>Bergeron A, Chevret S, Granata A, et al; ALLOZITHRO Study Investigators. Effect of azithromycin on airflow decline-free survival after allogeneic hematopoietic stem cell transplant: the ALLOZITHRO randomized clinical trial. <i>JAMA</i>. 2017;318(6):557-566. doi:10.1001/jama.2017.9938<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/28787506/pubmed" id="28787506" target="_blank">28787506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24229360">
<a name="24229360"></a>Berkhof FF, Doornewaard-ten Hertog NE, Uil SM, Kerstjens HA, van den Berg JW. Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. <i>Respir Res</i>. 2013;14:125. doi:10.1186/1465-9921-14-125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/24229360/pubmed" id="24229360" target="_blank">24229360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12635534">
<a name="12635534"></a>Bevan CD, Ridgway GL, Rothermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. <i>J Int Med Res</i>. 2003;31(1):45-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/12635534/pubmed" id="12635534" target="_blank">12635534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bhimraj.1">
<a name="Bhimraj.1"></a>Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. http://www.idsociety.org/COVID19guidelines. Updated September 25, 2020. Accessed October 19, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25748818">
<a name="25748818"></a>Bin Abdulhak AA, Khan AR, Garbati MA, et al. Azithromycin and risk of cardiovascular death: a meta-analytic review of observational studies. <i>Am J Ther</i>. 2015;22(5):e122-e129. doi:10.1097/MJT.0000000000000138<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25748818/pubmed" id="25748818" target="_blank">25748818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34310083">
<a name="34310083"></a>Boelig RC, Lam E, Rochani A, Kaushal G, Roman A, Kraft WK. Longitudinal evaluation of azithromycin and cytokine concentrations in amniotic fluid following one-time oral dosing in pregnancy. <i>Clin Transl Sci</i>. 2021;14(6):2431-2439. doi:10.1111/cts.13111<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/34310083/pubmed" id="34310083" target="_blank">34310083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2011;53(7):e25-e76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 25th ed. American Academy of Pediatrics; 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9142801">
<a name="9142801"></a>Brown BA, Griffith DE, Girard W, Levin J, Wallace RJ Jr. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. <i>Clin Infect Dis.</i> 1997;24(5):958-964. doi:10.1093/clinids/24.5.958<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/9142801/pubmed" id="9142801" target="_blank">9142801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23478961">
<a name="23478961"></a>Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. <i>Antimicrob Agents Chemother</i>. 2013;57(5):2326-2332. doi:10.1128/AAC.02176-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/23478961/pubmed" id="23478961" target="_blank">23478961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16755471">
<a name="16755471"></a>Bryant KA, Humbaugh K, Brothers K, et al, "Measures to Control an Outbreak of Pertussis in a Neonatal Intermediate Care Nursery After Exposure to a Healthcare Worker," <i>Infect Control Hosp Epidemiol</i>, 2006, 27(6):541-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/16755471/pubmed" id="16755471" target="_blank">16755471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10473232">
<a name="10473232"></a>Butler T, Sridhar CB, Daga MK, et al. Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India. <i>J Antimicrob Chemother</i>. 1999;44(2):243-250. doi:10.1093/jac/44.2.243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/10473232/pubmed" id="10473232" target="_blank">10473232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31360170">
<a name="31360170"></a>Butt MU, Jabri A, Elayi SC. Azithromycin-induced thrombocytopenia: a rare etiology of drug-induced immune thrombocytopenia. <i>Case Rep Med</i>. 2019;2019:6109831. doi:10.1155/2019/6109831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/31360170/pubmed" id="31360170" target="_blank">31360170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30899912">
<a name="30899912"></a>Callahan SJ, Vranic A, Flors L, Hanley M, Stoler MH, Mehrad B. Sporadic obliterative bronchiolitis: case series and systematic review of the literature. <i>Mayo Clin Proc Innov Qual Outcomes</i>. 2019;3(1):86-93. doi:10.1016/j.mayocpiqo.2018.10.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/30899912/pubmed" id="30899912" target="_blank">30899912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28497632">
<a name="28497632"></a>Campanón-Toro MV, Sierra O, Moreno E, Sobrino-García M, Gracia-Bara MT, Dávila I. Acute generalized exanthematous pustulosis (AGEP) induced by azithromycin. <i>Contact Dermatitis</i>. 2017;76(6):363-364. doi:10.1111/cod.12717<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/28497632/pubmed" id="28497632" target="_blank">28497632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11247598">
<a name="11247598"></a>Cascaval RI, Lancaster DJ. Hypersensitivity syndrome associated with azithromycin. <i>Am J Med</i>. 2001;110(4):330-331. doi:10.1016/s0002-9343(00)00724-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/11247598/pubmed" id="11247598" target="_blank">11247598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15909262">
<a name="15909262"></a>Casey JR, Pichichero ME. Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis. <i>Clin Infect Dis</i>. 2005;40(12):1748-1755. doi: 10.1086/430307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/15909262/pubmed" id="15909262" target="_blank">15909262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12749513">
<a name="12749513"></a>Castaldo RS, Celli BR, Gomez F, LaVallee N, Souhrada J, Hanrahan JP. A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. <i>Clin Ther</i>. 2003;25(2):542-557.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/12749513/pubmed" id="12749513" target="_blank">12749513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Cholera - Vibrio cholerae infection. Antibiotic treatment: recommendations for the use of antibiotics for the treatment of cholera. <a href="https://www.cdc.gov/cholera/treatment/antibiotic-treatment.html" target="_blank">https://www.cdc.gov/cholera/treatment/antibiotic-treatment.html</a>. Updated June 1, 2022. Accessed September 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2020">
<a name="CDC.2020"></a>Centers for Disease Control and Prevention (CDC). FAQs for clinicians about <i>C. diff</i>. <a href="https://www.cdc.gov/cdiff/clinicians/faq.html" target="_blank">https://www.cdc.gov/cdiff/clinicians/faq.html</a>. Published March 27, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention (CDC). For clinicians: pertussis treatment. <a href="https://www.cdc.gov/pertussis/clinical/treatment.html" target="_blank">https://www.cdc.gov/pertussis/clinical/treatment.html</a>. Updated August 4, 2022a. Accessed February 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19730409">
<a name="19730409"></a>Centers for Disease Control and Prevention (CDC). Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children. <i>MMWR Recomm Rep</i>. 2009;58(RR-11):1-166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/19730409/pubmed" id="19730409" target="_blank">19730409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21160459">
<a name="21160459"></a>Centers for Disease Control and Prevention (CDC). Sexually Transmitted Diseases Treatment Guidelines, 2010. <i>MMWR Recomm Rep</i>. 2010;59(RR-12):1-110.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/21160459/pubmed" id="21160459" target="_blank">21160459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention. The pretravel consultation: travelers' diarrhea. In: Centers for Disease Control and Prevention. <i>CDC Yellow Book 2018: Health Information for International Travel</i>. <a href="https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea" target="_blank">https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea</a>. Published June 13, 2017. Accessed May 10, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22874837">
<a name="22874837"></a>Centers for Disease Control and Prevention (CDC). Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections. <i>MMWR Morb Mortal Wkly Rep</i>. 2012;61(31):590-594.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22874837/pubmed" id="22874837" target="_blank">22874837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25754159">
<a name="25754159"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25754159/pubmed" id="25754159" target="_blank">25754159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. <i>Gastroenterology</i>. 2015;148(7):1340-52.e7. doi:10.1053/j.gastro.2015.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10858343">
<a name="10858343"></a>Chinh NT, Parry CM, Ly NT, et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. <i>Antimicrob Agents Chemother</i>. 2000;44(7):1855-1859. doi:10.1128/AAC.44.7.1855-1859.2000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/10858343/pubmed" id="10858343" target="_blank">10858343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32318706">
<a name="32318706"></a>Chiotos K, Hayes M, Kimberlin DW, et al. Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2. <i>J Pediatric Infect Dis Soc</i>. Published online April 22, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/32318706/pubmed" id="32318706" target="_blank">32318706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. <i>Clin Infect Dis</i>. 2012;54(8):e72-e112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25158669">
<a name="25158669"></a>Cocco G, Jerie P. Torsades de pointes induced by the concomitant use of ivabradine and azithromycin: an unexpected dangerous interaction. <i>Cardiovasc Toxicol</i>. 2015;15(1):104-106. doi:10.1007/s12012-014-9274-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25158669/pubmed" id="25158669" target="_blank">25158669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14770076">
<a name="14770076"></a>Cohen R. Defining the optimum treatment regimen for azithromycin in acute tonsillopharyngitis. <i>Pediatr Infect Dis J</i>. 2004;23(2)(suppl):S129-S134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/14770076/pubmed" id="14770076" target="_blank">14770076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36701253">
<a name="36701253"></a>Corrections. <i>MMWR Morb Mortal Wkly Rep</i>. 2023;72:107-108. doi:10.15585/mmwr.mm7204a5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/36701253/pubmed" id="36701253" target="_blank">36701253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14586869">
<a name="14586869"></a>Cotter CJ, Bierne JC. Azithromycin for odontogenic infection. <i>J Oral Maxillofac Surg</i>. 2003;61(10):1238; author reply 1238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/14586869/pubmed" id="14586869" target="_blank">14586869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9455502">
<a name="9455502"></a>Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. <i>Clin Infect Dis.</i> 1998;26(1):1-10; quiz 11-12. doi:10.1086/516284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/9455502/pubmed" id="9455502" target="_blank">9455502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11419669">
<a name="11419669"></a>Craig WA. The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy. <i>Respir Med</i>. 2001;95(suppl A):S12-S19; discussion S26-S27. doi:10.1016/s0954-6111(01)90023-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/11419669/pubmed" id="11419669" target="_blank">11419669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25784092">
<a name="25784092"></a>da Cunha Filho RR, Bordignon SC, Cassol M, Rastelli GJ. Acute generalized exanthematous pustulosis by azithromycin. <i>Int J Dermatol</i>. 2015;54(6):e247-e249. doi:10.1111/ijd.12778<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25784092/pubmed" id="25784092" target="_blank">25784092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12587634">
<a name="12587634"></a>Dakdouki GK, Obeid KH, Kanj SS. Azithromycin-induced rash in infectious mononucleosis. <i>Scand J Infect Dis</i>. 2002;34(12):939-941.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/12587634/pubmed" id="12587634" target="_blank">12587634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32797222">
<a name="32797222"></a>Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. <i>Clin Infect Dis.</i> 2020;71(4):905-913. doi:10.1093/cid/ciaa1125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/32797222/pubmed" id="32797222" target="_blank">32797222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26997729">
<a name="26997729"></a>Das A, Sancheti K, Podder I, Das NK. Azithromycin induced bullous fixed drug eruption. <i>Indian J Pharmacol</i>. 2016;48(1):83-85. doi:10.4103/0253-7613.174565<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/26997729/pubmed" id="26997729" target="_blank">26997729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1966617">
<a name="1966617"></a>Debbia EA, Molinari G, Paglia P, Schito GC. Post-antibiotic effect of azithromycin on respiratory tract pathogens. <i>Drugs Exp Clin Res</i>. 1990;16(12):615-619.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/1966617/pubmed" id="1966617" target="_blank">1966617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9527789">
<a name="9527789"></a>den Hollander JG, Knudsen JD, Mouton JW, et al. Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. <i>Antimicrob Agents Chemother.</i> 1998;42(2):377-382. doi:10.1128/AAC.42.2.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/9527789/pubmed" id="9527789" target="_blank">9527789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26810646">
<a name="26810646"></a>Deshpande D, Pasipanodya JG, Gumbo T. Azithromycin dose to maximize efficacy and suppress acquired drug resistance in pulmonary Mycobacterium avium disease. <i>Antimicrob Agents Chemother</i>. 2016;60(4):2157-2163. doi: 10.1128/AAC.02854-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/26810646/pubmed" id="26810646" target="_blank">26810646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23620467">
<a name="23620467"></a>Deshpande A, Pasupuleti V, Thota P, et al. Community-associated <i>Clostridium difficile</i> infection and antibiotics: a meta-analysis. <i>J Antimicrob Chemother</i>. 2013;68(9):1951-1961. doi:10.1093/jac/dkt129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/23620467/pubmed" id="23620467" target="_blank">23620467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18493312">
<a name="18493312"></a>Dolecek C, Tran TP, Nguyen NR, et al. A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam. <i>PLoS One</i>. 2008;3(5):e2188. doi:10.1371/journal.pone.0002188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/18493312/pubmed" id="18493312" target="_blank">18493312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1319048">
<a name="1319048"></a>Drew RH, Gallis HA. Azithromycin-Spectrum of Activity, Pharmacokinetics, and Clinical Applications. <i>Pharmacotherapy</i>. 1992;12(3):161-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/1319048/pubmed" id="1319048" target="_blank">1319048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19828533">
<a name="19828533"></a>DuPont HL. Clinical Practice. Bacterial Diarrhea. <i>N Engl J Med</i>. 2009;361(16):1560-1569.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/19828533/pubmed" id="19828533" target="_blank">19828533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31629365">
<a name="31629365"></a>Durukan D, Read TRH, Murray G, et al. Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and doxycycline-2.5 g azithromycin for the treatment of mycoplasma genitalium infection: efficacy and tolerability. <i>Clin Infect Dis</i>. 2020;71(6):1461-1468. doi:10.1093/cid/ciz1031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/31629365/pubmed" id="31629365" target="_blank">31629365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25687145">
<a name="25687145"></a>Eberly MD, Eide MB, Thompson JL, et al. Azithromycin in early infancy and pyloric stenosis. <i>Pediatrics</i>. 2015;135(3):483-488. doi:10.1542/peds.2014-2026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25687145/pubmed" id="25687145" target="_blank">25687145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12383667">
<a name="12383667"></a>Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. <i>Lancet</i>. 2002;360(9338):978-984.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/12383667/pubmed" id="12383667" target="_blank">12383667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27497265">
<a name="27497265"></a>Etminan M, Westerberg BD, Kozak FK, Guo MY, Carleton BC. Risk of sensorineural hearing loss with macrolide antibiotics: a nested case-control study. <i>Laryngoscope</i>. 2017;127(1):229-232. doi:10.1002/lary.26190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/27497265/pubmed" id="27497265" target="_blank">27497265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26283670">
<a name="26283670"></a>Falk L, Enger M, Jensen JS. Time to eradication of Mycoplasma genitalium after antibiotic treatment in men and women. <i>J Antimicrob Chemother</i>. 2015;70(11):3134-3140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/26283670/pubmed" id="26283670" target="_blank">26283670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ferguson.1">
<a name="Ferguson.1"></a>Ferguson GT. Management of refractory chronic obstructive pulmonary disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18611754">
<a name="18611754"></a>Ferrara A, Dos Santos C, Cimbro M, Grassi GG. Comparative antimicrobial activity and post-antibiotic effect of azithromycin, clarithromycin and roxithromycin against some respiratory pathogens. <i>Int J Antimicrob Agents.</i> 1996;7(3):181-186. doi:10.1016/s0924-8579(96)00320-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/18611754/pubmed" id="18611754" target="_blank">18611754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-File.1">
<a name="File.1"></a>File TM. Treatment of community-acquired pneumonia in adults in the outpatient setting. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 14, 2023a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-File.2018">
<a name="File.2018"></a>File TM. Treatment of community-acquired pneumonia in adults who require hospitalization. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 14, 2023b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22106226">
<a name="22106226"></a>Fischer JH, Sarto GE, Habibi M, et al. Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age. <i>Antimicrob Agents Chemother. </i>2012;56(2):715-724.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22106226/pubmed" id="22106226" target="_blank">22106226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26666259">
<a name="26666259"></a>Floto RA, Olivier KN, Saiman L, et al; US Cystic Fibrosis Foundation and European Cystic Fibrosis Society. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. <i>Thorax</i>. 2016;71(suppl 1):1-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/26666259/pubmed" id="26666259" target="_blank">26666259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration (FDA). FDA drug safety communication. FDA warns about increased risk of cancer relapse with long-term use of azithromycin (Zithromycin, Zmax) antibiotic after donor stem cell transplant. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-cancer-relapse-long-term-use-azithromycin-zithromax-zmax-antibiotic" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-cancer-relapse-long-term-use-azithromycin-zithromax-zmax-antibiotic</a>. Published August 3, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2154441">
<a name="2154441"></a>Foulds G, Shepard RM, Johnson RB. The Pharmacokinetics of Azithromycin in Human Serum and Tissues. <i>J Antimicrob Chemother</i>. 1990;25(suppl A):73-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/2154441/pubmed" id="2154441" target="_blank">2154441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21258094">
<a name="21258094"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):e56-e93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/21258094/pubmed" id="21258094" target="_blank">21258094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15034826">
<a name="15034826"></a>Frenck RW Jr, Mansour A, Nakhla I, et al. Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. <i>Clin Infect Dis</i>. 2004;38(7):951-957. doi:10.1086/382359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/15034826/pubmed" id="15034826" target="_blank">15034826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11073741">
<a name="11073741"></a>Frenck RW Jr, Nakhla I, Sultan Y, et al. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. <i>Clin Infect Dis</i>. 2000;31(5):1134-1138. doi:10.1086/317450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/11073741/pubmed" id="11073741" target="_blank">11073741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25398062">
<a name="25398062"></a>García JC, Núñez MJ, Castro B, Fernández JM, Portillo A, Oteo JA. Hepatosplenic cat scratch disease in immunocompetent adults: report of 3 cases and review of the literature. <i>Medicine (Baltimore)</i>. 2014;93(17):267-279. doi:10.1097/MD.0000000000000089<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25398062/pubmed" id="25398062" target="_blank">25398062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19246689">
<a name="19246689"></a>Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. <i>Circulation</i>. 2009;119(11):1541-1551. doi:10.1161/CIRCULATIONAHA.109.191959<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/19246689/pubmed" id="19246689" target="_blank">19246689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22080265">
<a name="22080265"></a>Ghanem KG, Workowski KA. Management of adult syphilis. <i>Clin Infect Dis.</i> 2011;53(suppl 3):110-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22080265/pubmed" id="22080265" target="_blank">22080265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10348767">
<a name="10348767"></a>Girgis NI, Butler T, Frenck RW, et al. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. <i>Antimicrob Agents Chemother</i>. 1999;43(6):1441-1444. doi:10.1128/AAC.43.6.1441<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/10348767/pubmed" id="10348767" target="_blank">10348767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24001961">
<a name="24001961"></a>Giudicessi JR, Ackerman MJ. Azithromycin and risk of sudden cardiac death: guilty as charged or falsely accused?. <i>Cleve Clin J Med</i>. 2013;80(9):539-544. doi:10.3949/ccjm.80a.13077<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/24001961/pubmed" id="24001961" target="_blank">24001961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.1">
<a name="GOLD.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2022 report. https://goldcopd.org/2023-gold-report-2/. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GTFCC.1">
<a name="GTFCC.1"></a>Global Task Force on Cholera Control (GTFCC). Cholera outbreak response field manual. https://www.gtfcc.org/wp-content/uploads/2020/04/gtfcc-cholera-outbreak-response-field-manual.pdf. Published October 2019. Accessed September 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19366316">
<a name="19366316"></a>Goldstein LH, Berlin M, Tsur L, et al. The safety of macrolides during lactation. <i>Breastfeed Med.</i> 2009;4(4):197-200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/19366316/pubmed" id="19366316" target="_blank">19366316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18192909">
<a name="18192909"></a>Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. <i>Transplantation</i>. 2008;85(1):36-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/18192909/pubmed" id="18192909" target="_blank">18192909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Griffith.2018">
<a name="Griffith.2018"></a>Griffith DE. Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17277290">
<a name="17277290"></a>Griffith DE, Aksamit T, Brown-Elliott BA, et al; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Diseases Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. <i>Am J Respir Crit Care Med</i>. 2007;175(4):367-416.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/17277290/pubmed" id="17277290" target="_blank">17277290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11340525">
<a name="11340525"></a>Griffith DE, Brown BA, Girard WM, Griffith BE, Couch LA, Wallace RJ Jr. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. <i>Clin Infect Dis</i>. 2001;32(11):1547-1553. doi:10.1086/320512<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/11340525/pubmed" id="11340525" target="_blank">11340525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9849993">
<a name="9849993"></a>Hammerschlag MR, Gelling M, Roblin PM, Kutlin A, Jule JE. Treatment of neonatal chlamydial conjunctivitis with azithromycin. <i>Pediatr Infect Dis J</i>. 1998;17(11):1049-1050.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/9849993/pubmed" id="9849993" target="_blank">9849993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25165550">
<a name="25165550"></a>Hancox JC, Hasnain M, Vieweg WV, Crouse EL, Baranchuk A. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports. <i>Ther Adv Infect Dis</i>. 2013;1(5):155-165. doi:10.1177/2049936113501816<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25165550/pubmed" id="25165550" target="_blank">25165550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26785402">
<a name="26785402"></a>Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians (ACP) and the Centers for Disease Control and Prevention (CDC). <i>Ann Intern Med</i>. 2016;164(6):425-434. doi:10.7326/M15-1840<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/26785402/pubmed" id="26785402" target="_blank">26785402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21098694">
<a name="21098694"></a>Hassan HE, Othman AA, Eddington ND, et al. Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia. <i>J Clin Pharmacol.</i> 2011;51(9):1264-1275. doi:10.1177/0091270010382021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/21098694/pubmed" id="21098694" target="_blank">21098694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29054853">
<a name="29054853"></a>Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). <i>Thorax</i>. 2017;72(suppl 2):ii1-ii64. doi:10.1136/thoraxjnl-2017-210927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/29054853/pubmed" id="29054853" target="_blank">29054853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy.</i> 2009;29(5):562-577. doi:10.1592/phco.29.5.562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146873">
<a name="22146873"></a>Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for <i>Clostridium difficile</i> infection after exposure to antibiotics. <i>J Antimicrob Chemother</i>. 2012;67(3):742-748. doi:10.1093/jac/dkr508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22146873/pubmed" id="22146873" target="_blank">22146873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8655206">
<a name="8655206"></a>Höffler D, Koeppe P, Paeske B. Pharmacokinetics of azithromycin in normal and impaired renal function. <i>Infection</i>. 1995;23(6):356-361. doi:10.1007/bf01713565<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/8655206/pubmed" id="8655206" target="_blank">8655206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18070319">
<a name="18070319"></a>Huang BH, Wu CH, Hsia CP, Yin Chen C. Azithromycin-induced torsade de pointes. <i>Pacing Clin Electrophysiol</i>. 2007;30(12):1579-1582. doi:10.1111/j.1540-8159.2007.00912.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/18070319/pubmed" id="18070319" target="_blank">18070319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24255774">
<a name="24255774"></a>Hui D, Yan F, Chen RH. The effects of azithromycin on patients with diffuse panbronchiolitis: a retrospective study of 29 cases. <i>J Thorac Dis</i>. 2013;5(5):613-617. doi:10.3978/j.issn.2072-1439.2013.09.01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/24255774/pubmed" id="24255774" target="_blank">24255774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34541478">
<a name="34541478"></a>Hume-Nixon M, Quach A, Reyburn R, Nguyen C, Steer A, Russell F. A systematic review and meta-analysis of the effect of administration of azithromycin during pregnancy on perinatal and neonatal outcomes. <i>EClinicalMedicine</i>. 2021;40:101123. doi:10.1016/j.eclinm.2021.101123<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/34541478/pubmed" id="34541478" target="_blank">34541478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17583109">
<a name="17583109"></a>Isik SR, Karakaya G, Erkin G, Kalyoncu AF. Multidrug-induced erythema multiforme. <i>J Investig Allergol Clin Immunol</i>. 2007;17(3):196-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/17583109/pubmed" id="17583109" target="_blank">17583109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15665708">
<a name="15665708"></a>Jacobs RF, Maples HD, Aranda JV, et al. Pharmacokinetics of intravenously administered azithromycin in pediatric patients. <i>Pediatr Infect Dis J.</i> 2005;24(1):34-39. doi:10.1097/01.inf.0000148927.48680.fc<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/15665708/pubmed" id="15665708" target="_blank">15665708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20133163">
<a name="20133163"></a>Jain R, Hachem RR, Morrell MR, et al. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. <i>J Heart Lung Transplant</i>. 2010;29(5):531-537.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/20133163/pubmed" id="20133163" target="_blank">20133163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27480854">
<a name="27480854"></a>Jeong BH, Jeon K, Park HY, et al. Peak plasma concentration of azithromycin and treatment responses in Mycobacterium avium complex lung disease. <i>Antimicrob Agents Chemother</i>. 2016;60(10):6076-6083. doi:10.1128/AAC.00770-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/27480854/pubmed" id="27480854" target="_blank">27480854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kasperbauer.2018">
<a name="Kasperbauer.2018"></a>Kasperbauer S, Daly CL. Treatment of Mycobacterium avium complex lung infection in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19578229">
<a name="19578229"></a>Kaushik JS, Gupta P, Faridi MM, Das S. Single dose azithromycin versus ciprofloxacin for cholera in children: a randomized controlled trial. <i>Indian Pediatr</i>. 2010;47(4):309-315. doi:10.1007/s13312-010-0059-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/19578229/pubmed" id="19578229" target="_blank">19578229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8178871">
<a name="8178871"></a>Kelsey JJ, Moser LR, Jennings JC, et al. Presence of azithromycin breast milk concentrations: a case report. <i>Am J Obstet Gynecol.</i> 1994;170(5, pt 1):1375-1376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/8178871/pubmed" id="8178871" target="_blank">8178871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11587400">
<a name="11587400"></a>Kent JR, Almond MK, Dhillon S. Azithromycin: an assessment of its pharmacokinetics and therapeutic potential in CAPD. <i>Perit Dial Int.</i> 2001;21(4):372-377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/11587400/pubmed" id="11587400" target="_blank">11587400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36549458">
<a name="36549458"></a>Keskin-Arslan E, Erol H, Uysal N, Karadas B, Temiz T, Kaplan YC. Pregnancy outcomes following maternal macrolide use: a systematic review and meta- analysis. <i>Reprod Toxicol</i>. 2023;115:124-146. doi:10.1016/j.reprotox.2022.12.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/36549458/pubmed" id="36549458" target="_blank">36549458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17546486">
<a name="17546486"></a>Kezerashvili A, Khattak H, Barsky A, Nazari R, Fisher JD. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. <i>J Interv Card Electrophysiol</i>. 2007;18(3):243-246. doi:10.1007/s10840-007-9124-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/17546486/pubmed" id="17546486" target="_blank">17546486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12480424">
<a name="12480424"></a>Khan WA, Saha D, Rahman A, Salam MA, Bogaerts J, Bennish ML. Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial. <i>Lancet</i>. 2002;360(9347):1722-1727. doi:10.1016/S0140-6736(02)11680-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/12480424/pubmed" id="12480424" target="_blank">12480424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16359290">
<a name="16359290"></a>Kim MH, Berkowitz C, Trohman RG. Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. <i>Pacing Clin Electrophysiol</i>. 2005;28(11):1221-1222. doi:10.1111/j.1540-8159.2005.50146.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/16359290/pubmed" id="16359290" target="_blank">16359290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-King.1">
<a name="King.1"></a>King TE Jr. Diffuse panbronchiolitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 4, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-King.2020">
<a name="King.2020"></a>King TE Jr. Overview of bronchiolar disorders in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28399851">
<a name="28399851"></a>Kletsova EA, Spitzer ED, Fries BC, Marcos LA. Babesiosis in Long Island: review of 62 cases focusing on treatment with azithromycin and atovaquone. <i>Ann Clin Microbiol Antimicrob</i>. 2017;16(1):26. doi:10.1186/s12941-017-0198-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/28399851/pubmed" id="28399851" target="_blank">28399851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12526069">
<a name="12526069"></a>Kogan R, Martínez MA, Rubilar L, et al. Comparative Randomized Trial of Azithromycin versus Erythromycin and Amoxicillin for Treatment of Community-acquired Pneumonia in Children. <i>Pediatr Pulmonol.</i> 2003;35(2):91-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/12526069/pubmed" id="12526069" target="_blank">12526069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33501959">
<a name="33501959"></a>Krause PJ, Auwaerter PG, Bannuru RR, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA): 2020 guideline on diagnosis and management of babesiosis. <i>Clin Infect Dis</i>. 2021;72(2):185-189. doi:10.1093/cid/ciab050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/33501959/pubmed" id="33501959" target="_blank">33501959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18181735">
<a name="18181735"></a>Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. <i>Clin Infect Dis</i>. 2008;46(3):370-376. doi:10.1086/525852<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/18181735/pubmed" id="18181735" target="_blank">18181735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11078770">
<a name="11078770"></a>Krause PJ, Lepore T, Sikand VK, et al. Atovaquone and azithromycin for the treatment of babesiosis. <i>N Engl J Med</i>. 2000;343(20):1454-1458. doi:10.1056/NEJM200011163432004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/11078770/pubmed" id="11078770" target="_blank">11078770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15807672">
<a name="15807672"></a>Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. <i>Clin Exp Dermatol</i>. 2005;30(3):215-220. doi:10.1111/j.1365-2230.2005.01769.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/15807672/pubmed" id="15807672" target="_blank">15807672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10201465">
<a name="10201465"></a>Laine L, Estrada R, Trujillo M, et al. Once-daily therapy for <i>H. pylori</i> infection: a randomized comparison of four regimens. <i>Am J Gastroenterol</i>. 1999;94(4):962-966. doi:10.1111/j.1572-0241.1999.995_r.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/10201465/pubmed" id="10201465" target="_blank">10201465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32211414">
<a name="32211414"></a>Lambert JS. An overview of tickborne infections in pregnancy and outcomes in the newborn: the need for prospective studies. <i>Front Med (Lausanne)</i>. 2020;7:72. doi:10.3389/fmed.2020.00072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/32211414/pubmed" id="32211414" target="_blank">32211414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33251700">
<a name="33251700"></a>Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis, and treatment of lyme disease. <i>Arthritis Care Res (Hoboken)</i>. 2021;73(1):1-9. doi:10.1002/acr.24495<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/33251700/pubmed" id="33251700" target="_blank">33251700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28002638">
<a name="28002638"></a>Lanvers-Kaminsky C, Zehnhoff-Dinnesen AA, Parfitt R, Ciarimboli G. Drug-induced ototoxicity: mechanisms, pharmacogenetics, and protective strategies. <i>Clin Pharmacol Ther</i>. 2017;101(4):491-500. doi:10.1002/cpt.603<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/28002638/pubmed" id="28002638" target="_blank">28002638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LaRocque.1">
<a name="LaRocque.1"></a>LaRocque R, Harris JB. Traveler’s diarrhea: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26240201">
<a name="26240201"></a>Lau A, Bradshaw CS, Lewis D, et al. The efficacy of azithromycin for the treatment of genital Mycoplasma genitalium: a systematic review and meta-analysis. <i>Clin Infect Dis</i>. 2015;61(9):1389-1399. doi:10.1093/cid/civ644<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/26240201/pubmed" id="26240201" target="_blank">26240201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24944120">
<a name="24944120"></a>Leibovici-Weissman Y, Neuberger A, Bitterman R, Sinclair D, Salam MA, Paul M. Antimicrobial drugs for treating cholera. <i>Cochrane Database Syst Rev</i>. 2014;2014(6):CD008625. doi:10.1002/14651858.CD008625.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/24944120/pubmed" id="24944120" target="_blank">24944120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33454317">
<a name="33454317"></a>Leke AZ, Dolk H, Loane M, et al. Macrolide and lincosamide antibiotic exposure in the first trimester of pregnancy and risk of congenital anomaly: a European case-control study. <i>Reprod Toxicol</i>. 2021;100:101-108. doi:10.1016/j.reprotox.2021.01.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/33454317/pubmed" id="33454317" target="_blank">33454317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24189261">
<a name="24189261"></a>Li H, Liu DH, Chen LL, et al. Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. <i>Antimicrob Agents Chemother</i>. 2014;58(1):511-517. doi:10.1128/AAC.02067-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/24189261/pubmed" id="24189261" target="_blank">24189261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21841323">
<a name="21841323"></a>Li H, Zhou Y, Fan F, et al. Effect of azithromycin on patients with diffuse panbronchiolitis: retrospective study of 51 cases. <i>Intern Med.</i> 2011;50(16):1663-1669. doi:10.2169/internalmedicine.50.4727<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/21841323/pubmed" id="21841323" target="_blank">21841323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23439909">
<a name="23439909"></a>Lieberthal AS, Carroll AE, Chonmaitree T, et al. The Diagnosis and Management of Acute Otitis Media. <i>Pediatrics</i>. 2013;131(3):e964-e999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/23439909/pubmed" id="23439909" target="_blank">23439909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17060516">
<a name="17060516"></a>Liu P, Allaudeen H, Chandra R, et al. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. <i>Antimicrob Agents Chemother.</i> 2007;51(1):103-109. doi:10.1128/AAC.00852-06<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/17060516/pubmed" id="17060516" target="_blank">17060516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20479103">
<a name="20479103"></a>Lockwood AM, Cole S, Rabinovich M. Azithromycin-Induced Liver Injury. <i>Am J Health Syst Pharm</i>. 2010;67(10):810-814.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/20479103/pubmed" id="20479103" target="_blank">20479103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25494485">
<a name="25494485"></a>Lu ZK, Yuan J, Li M, et al. Cardiac risks associated with antibiotics: azithromycin and levofloxacin. <i>Expert Opin Drug Saf</i>. 2015;14(2):295-303. doi:10.1517/14740338.2015.989210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25494485/pubmed" id="25494485" target="_blank">25494485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24618148">
<a name="24618148"></a>Lund M, Pasternak B, Davidsen RB, et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. <i>BMJ</i>. 2014;348:1908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/24618148/pubmed" id="24618148" target="_blank">24618148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25859365">
<a name="25859365"></a>Ma TK, Chow KM, Choy AS, Kwan BC, Szeto CC, Li PK. Clinical manifestation of macrolide antibiotic toxicity in CKD and dialysis patients.<i> Clin Kidney J.</i> 2014;7(6):507-512. doi:10.1093/ckj/sfu098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25859365/pubmed" id="25859365" target="_blank">25859365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16267717">
<a name="16267717"></a>Mackell S. Traveler's Diarrhea in the Pediatric Population: Etiology and Impact. <i>Clin Infect Dis</i>. 2005;41(suppl 80):S547-S552.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/16267717/pubmed" id="16267717" target="_blank">16267717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21548512">
<a name="21548512"></a>Maleszka R, Turek-Urasinska K, Oremus M, Vukovic J, Barsic B. Pulsed azithromycin treatment is as effective and safe as 2-week-longer daily doxycycline treatment of acne vulgaris: a randomized, double-blind, noninferiority study. <i>Skinmed</i>. 2011;9(2):86-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/21548512/pubmed" id="21548512" target="_blank">21548512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31721138">
<a name="31721138"></a>Mallah N, Tohidinik HR, Etminan M, Figueiras A, Takkouche B. Prenatal exposure to macrolides and risk of congenital malformations: a meta-analysis. <i>Drug Saf</i>. 2020;43(3):211-221. doi:10.1007/s40264-019-00884-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/31721138/pubmed" id="31721138" target="_blank">31721138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25111234">
<a name="25111234"></a>Martinez MA, Vuppalanchi R, Fontana RJ, et al. Clinical and histologic features of azithromycin-induced liver injury. <i>Clin Gastroenterol Hepatol</i>. 2015;13(2):369-376.e3. doi:10.1016/j.cgh.2014.07.054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25111234/pubmed" id="25111234" target="_blank">25111234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14615808">
<a name="14615808"></a>Matsunaga N, Oki Y, Prigollini A. A case of QT-interval prolongation precipitated by azithromycin. <i>N Z Med J</i>. 2003;116(1185):U666.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/14615808/pubmed" id="14615808" target="_blank">14615808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29890086">
<a name="29890086"></a>Mayer-Hamblett N, Retsch-Bogart G, Kloster M, et al. Azithromycin for early <i>Pseudomonas</i> infection in cystic fibrosis. The OPTIMIZE randomized trial. <i>Am J Respir Crit Care Med</i>. 2018;198(9):1177-1187. doi:10.1164/rccm.201802-0215OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/29890086/pubmed" id="29890086" target="_blank">29890086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for <i>Clostridium difficile</i> infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25385115">
<a name="25385115"></a>Merchan LM, Hassan HE, Terrin ML, et al. Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization. <i>Antimicrob Agents Chemother</i>. 2015;59(1):570-578. doi:10.1128/AAC.03951-14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25385115/pubmed" id="25385115" target="_blank">25385115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25359357">
<a name="25359357"></a>Meyer KC, Raghu G, Verleden GM, et al; ISHLT/ATS/ERS BOS Task Force Committee. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. <i>Eur Respir J</i>. 2014;44(6):1479-1503.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25359357/pubmed" id="25359357" target="_blank">25359357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12235254">
<a name="12235254"></a>Milberg P, Eckardt L, Bruns HJ, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. <i>J Pharmacol Exp Ther</i>. 2002;303(1):218-225. doi:10.1124/jpet.102.037911<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/12235254/pubmed" id="12235254" target="_blank">12235254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23540878">
<a name="23540878"></a>Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al; Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. <i>Am J Respir Crit Care Med</i>. 2013;187(7):680-689.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/23540878/pubmed" id="23540878" target="_blank">23540878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24674687">
<a name="24674687"></a>Mori F, Pecorari L, Pantano S, et al. Azithromycin anaphylaxis in children. <i>Int J Immunopathol Pharmacol</i>. 2014;27(1):121-126. doi:10.1177/039463201402700116<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/24674687/pubmed" id="24674687" target="_blank">24674687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24893087">
<a name="24893087"></a>Mortensen EM, Halm EA, Pugh MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. <i>JAMA</i>. 2014;311(21):2199-2208. doi:10.1001/jama.2014.4304<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/24893087/pubmed" id="24893087" target="_blank">24893087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8383944">
<a name="8383944"></a>Nahata MC, Koranyi KI, Gadgil SD, Hilligoss DM, Fouda HG, Gardner MJ. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. <i>Antimicrob Agents Chemother</i>. 1993;37(2):314-316. doi:10.1128/AAC.37.2.314<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/8383944/pubmed" id="8383944" target="_blank">8383944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7486938">
<a name="7486938"></a>Nahata MC, Koranyi KI, Luke DR, Foulds G. Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. <i>Antimicrob Agents Chemother.</i> 1995;39(8):1875-1877. doi:10.1128/AAC.39.8.1875<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/7486938/pubmed" id="7486938" target="_blank">7486938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26194400">
<a name="26194400"></a>Nappe TM, Goren-Garcia SL, Jacoby JL. Stevens-Johnson syndrome after treatment with azithromycin: an uncommon culprit. <i>Am J Emerg Med</i>. 2016;34(3):676.e1-676.e6763. doi:10.1016/j.ajem.2015.06.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/26194400/pubmed" id="26194400" target="_blank">26194400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. Clinical guideline 183. https://www.nice.org.uk/guidance/cg183. Published September 3, 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31661302">
<a name="31661302"></a>Nichols DP, Odem-Davis K, Cogen JD, et al. Pulmonary outcomes associated with long-term azithromycin therapy in cystic fibrosis. <i>Am J Respir Crit Care Med</i>. 2020;201(4):430-437. doi:10.1164/rccm.201906-1206OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/31661302/pubmed" id="31661302" target="_blank">31661302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28315732">
<a name="28315732"></a>Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2017;70(2):252-289. doi:10.1016/j.jacc.2017.03.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/28315732/pubmed" id="28315732" target="_blank">28315732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32894857">
<a name="32894857"></a>Nunes CR, Procianoy RS, Corso AL, Silveira RC. Use of azithromycin for the prevention of lung injury in mechanically ventilated preterm neonates: a randomized controlled trial. <i>Neonatology</i>. 2020;117(4):522-528. doi:10.1159/000509462<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/32894857/pubmed" id="32894857" target="_blank">32894857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8922571">
<a name="8922571"></a>O'Doherty B. Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Paediatric Azithromycin Study Group. <i>Eur J Clin Microbiol Infect Dis</i>. 1996;15(9):718-724.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/8922571/pubmed" id="8922571" target="_blank">8922571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33332150">
<a name="33332150"></a>Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2021;143(5):e72-e227. doi:10.1161/CIR.0000000000000923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/33332150/pubmed" id="33332150" target="_blank">33332150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17145784">
<a name="17145784"></a>Parry CM, Ho VA, Phuong le T, et al. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. <i>Antimicrob Agents Chemother</i>. 2007;51(3):819-825. doi:10.1128/AAC.00447-06<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/17145784/pubmed" id="17145784" target="_blank">17145784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11280457">
<a name="11280457"></a>Parsad D, Pandhi R, Nagpal R, Negi KS. Azithromycin monthly pulse vs daily doxycycline in the treatment of acne vulgaris. <i>J Dermatol</i>. 2001;28(1):1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/11280457/pubmed" id="11280457" target="_blank">11280457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pichichero.1">
<a name="Pichichero.1"></a>Pichichero ME. Treatment and prevention of streptococcal pharyngitis in adults and children. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pilewski.2018">
<a name="Pilewski.2018"></a>Pilewski J. Chronic lung allograft dysfunction: Bronchiolitis obliterans. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28889110">
<a name="28889110"></a>Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. <i>Eur Respir J</i>. 2017;50(3):1700629. doi:10.1183/13993003.00629-2017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/28889110/pubmed" id="28889110" target="_blank">28889110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Powell.1">
<a name="Powell.1"></a>Powell AM, Nyirjesy P. Acute cervicitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 27, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19587486">
<a name="19587486"></a>Pradhan S, Pardasani V, Ramteke K. Azithromycin-induced myasthenic crisis: reversibility with calcium gluconate. <i>Neurol India</i>. 2009;57(3):352-353. doi:10.4103/0028-3886.53270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/19587486/pubmed" id="19587486" target="_blank">19587486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22391473">
<a name="22391473"></a>Psarros G, Riddell J 4th, Gandhi T, Kauffman CA, Cinti SK. Bartonella henselae infections in solid organ transplant recipients: report of 5 cases and review of the literature. <i>Medicine (Baltimore)</i>. 2012;91(2):111-121. doi:10.1097/MD.0b013e31824dc07a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22391473/pubmed" id="22391473" target="_blank">22391473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19189924">
<a name="19189924"></a>Pursnani A, Yee H, Slater W, Sarswat N. Hypersensitivity myocarditis associated with azithromycin exposure. <i>Ann Intern Med</i>. 2009;150(3):225-226. doi:10.7326/0003-4819-150-3-200902030-00027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/19189924/pubmed" id="19189924" target="_blank">19189924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7752216">
<a name="7752216"></a>Ramadan MA, Tawfik AF, Shibl AM, Gemmell CG. Post-antibiotic effect of azithromycin and erythromycin on streptococcal susceptibility to phagocytosis. <i>J Med Microbiol.</i> 1995;42(5):362-366. doi:10.1099/00222615-42-5-362<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/7752216/pubmed" id="7752216" target="_blank">7752216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17123995">
<a name="17123995"></a>Ramsey PS, Vaules MB, Vasdev GM, et al. Maternal and transplacental pharmacokinetics of azithromycin. <i>Am J Obstet Gynecol.</i> 2003;188(3):714-718.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/17123995/pubmed" id="17123995" target="_blank">17123995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24615307">
<a name="24615307"></a>Rao GA, Mann JR, Shoaibi A, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. <i>Ann Fam Med</i>. 2014;12(2):121-127. doi:10.1370/afm.1601<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/24615307/pubmed" id="24615307" target="_blank">24615307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22591294">
<a name="22591294"></a>Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. <i>N Engl J Med</i>. 2012;366(20):1881-1890. doi:10.1056/NEJMoa1003833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22591294/pubmed" id="22591294" target="_blank">22591294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29873691">
<a name="29873691"></a>Read TRH, Fairley CK, Murray GL, et al. Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation. <i>Clin Infect Dis</i>. 2019;68(4):554-560. doi:10.1093/cid/ciy477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/29873691/pubmed" id="29873691" target="_blank">29873691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10778901">
<a name="10778901"></a>Ress BD, Gross EM. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report. <i>Ann Otol Rhinol Laryngol</i>. 2000;109(4):435-437. doi:10.1177/000348940010900416<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/10778901/pubmed" id="10778901" target="_blank">10778901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28521004">
<a name="28521004"></a>Riddle MS, Connor BA, Beeching NJ, et al. Guidelines for the prevention and treatment of travelers’ diarrhea: a graded expert panel report. <i>J Travel Med.</i> 2017;24(suppl 1):S57-S74. doi:10.1093/jtm/tax026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/28521004/pubmed" id="28521004" target="_blank">28521004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27068718">
<a name="27068718"></a>Riddle MS, DuPont HL, Connor BA. ACG clinical guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. <i>Am J Gastroenterol</i>. 2016;111(5):602-622. doi:10.1038/ajg.2016.126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/27068718/pubmed" id="27068718" target="_blank">27068718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33080070">
<a name="33080070"></a>Rizk HG, Lee JA, Liu YF, Endriukaitis L, Isaac JL, Bullington WM. Drug-induced ototoxicity: a comprehensive review and reference guide. <i>Pharmacotherapy</i>. 2020;40(12):1265-1275. doi:10.1002/phar.2478<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/33080070/pubmed" id="33080070" target="_blank">33080070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013‐1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36410937">
<a name="36410937"></a>Ronzoni S, Boucoiran I, Yudin MH, et al. Guideline No. 430: Diagnosis and management of preterm prelabour rupture of membranes. <i>J Obstet Gynaecol Can</i>. 2022;44(11):1193-1208.e1. doi:10.1016/j.jogc.2022.08.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/36410937/pubmed" id="36410937" target="_blank">36410937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25832968">
<a name="25832968"></a>Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(2)(suppl):S1-S39. doi:10.1177/0194599815572097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25832968/pubmed" id="25832968" target="_blank">25832968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-RCOG.2015">
<a name="RCOG.2015"></a>Royal College of Obstetricians and Gynaecologists (RCOG). Best practice in comprehensive abortion care. Best Practice Paper No. 2. https://www.rcog.org.uk/media/geify5bx/abortion-care-best-practice-paper-april-2022.pdf. Published June 2015. Accessed February 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16856707">
<a name="16856707"></a>Russo V, Puzio G, Siniscalchi N. Azithromycin-induced QT prolongation in elderly patient. <i>Acta Biomed</i>. 2006;77(1):30-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/16856707/pubmed" id="16856707" target="_blank">16856707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33767665">
<a name="33767665"></a>Rybak LP, Ramkumar V, Mukherjea D. Ototoxicity of non-aminoglycoside antibiotics. <i>Front Neurol</i>. 2021;12:652674. doi:10.3389/fneur.2021.652674<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/33767665/pubmed" id="33767665" target="_blank">33767665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30043070">
<a name="30043070"></a>Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. <i>JAMA</i>. 2018;320(4):379-396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/30043070/pubmed" id="30043070" target="_blank">30043070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16760445">
<a name="16760445"></a>Saha D, Karim MM, Khan WA, Ahmed S, Salam MA, Bennish ML. Single-dose azithromycin for the treatment of cholera in adults. <i>N Engl J Med</i>. 2006;354(23):2452-2462.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/16760445/pubmed" id="16760445" target="_blank">16760445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20442386">
<a name="20442386"></a>Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with <i>Pseudomonas aeruginosa</i>: a randomized controlled trial. <i>JAMA</i>. 2010;303(17):1707-1715.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/20442386/pubmed" id="20442386" target="_blank">20442386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14519709">
<a name="14519709"></a>Saiman L, Marshall BC, Mayer-Hamblett N, et al; Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. <i>JAMA</i>. 2003;290(13):1749-1756. doi:10.1001/jama.290.13.1749<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/14519709/pubmed" id="14519709" target="_blank">14519709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22684984">
<a name="22684984"></a>Saiman L, Mayer-Hamblett N, Anstead M, et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with <i>Pseudomonas aeruginosa</i>. <i>Pediatr Pulmonol</i>. 2012;47(7):641-648. doi:10.1002/ppul.21601<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22684984/pubmed" id="22684984" target="_blank">22684984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26711756">
<a name="26711756"></a>Salman S, Davis TM, Page-Sharp M, et al. Pharmacokinetics of transfer of azithromycin into the breast milk of African mothers. <i>Antimicrob Agents Chemother</i>. 2015;60(3):1592-1599. doi:10.1128/AAC.02668-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/26711756/pubmed" id="26711756" target="_blank">26711756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11707055">
<a name="11707055"></a>Samarendra P, Kumari S, Evans SJ, Sacchi TJ, Navarro V. QT prolongation associated with azithromycin/amiodarone combination. <i>Pacing Clin Electrophysiol</i>. 2001;24(10):1572-1574. doi:10.1046/j.1460-9592.2001.01572.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/11707055/pubmed" id="11707055" target="_blank">11707055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27115378">
<a name="27115378"></a>Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. <i>JAMA</i>. 2016;315(16):1767-1777. doi:10.1001/jama.2016.2884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/27115378/pubmed" id="27115378" target="_blank">27115378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20391905">
<a name="20391905"></a>Santos N, Oliveira M, Galrinho A, Oliveira JA, Ferreira L, Ferreira R. QT interval prolongation and extreme bradycardia after a single dose of azithromycin. <i>Rev Port Cardiol</i>. 2010;29(1):139-142.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/20391905/pubmed" id="20391905" target="_blank">20391905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12075761">
<a name="12075761"></a>Schaad UB, Kellerhals P, Altwegg M; Swiss Pharyngitis Study Group. Azithromycin versus penicillin V for treatment of acute group A streptococcal pharyngitis. <i>Pediatr Infect Dis J</i>. 2002;21(4):304-308.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/12075761/pubmed" id="12075761" target="_blank">12075761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20859738">
<a name="20859738"></a>Schiff E, May K, Goldstein LH. Neuropsychiatric manifestations associated with azithromycin in two brothers. <i>Eur J Clin Pharmacol</i>. 2010;66(12):1273-1275. doi:10.1007/s00228-010-0900-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/20859738/pubmed" id="20859738" target="_blank">20859738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30035266">
<a name="30035266"></a>Schiffman SS. Influence of medications on taste and smell. <i>World J Otorhinolaryngol Head Neck Surg</i>. 2018;4(1):84-91. doi:10.1016/j.wjorl.2018.02.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/30035266/pubmed" id="30035266" target="_blank">30035266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1662637">
<a name="1662637"></a>Schönwald S, Skerk V, Petricevic I, Car V, Majerus-Misic L, Gunjaca M. Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia. <i>Eur J Clin Microbiol Infect Dis</i>. 1991;10(10):877-880.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/1662637/pubmed" id="1662637" target="_blank">1662637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sena.1">
<a name="Sena.1"></a>Seña AC, Cohen MS. Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae</i> infection) in adults and adolescents. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sethi.1">
<a name="Sethi.1"></a>Sethi S, Murphy TF. Management of infection in exacerbations of chronic obstructive pulmonary disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31540456">
<a name="31540456"></a>Shaeer KM, Chahine EB, Varghese Gupta S, Cho JC. Macrolide allergic reactions. <i>Pharmacy (Basel)</i>. 2019;7(3):135. doi:10.3390/pharmacy7030135<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/31540456/pubmed" id="31540456" target="_blank">31540456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29053792">
<a name="29053792"></a>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. <i>Clin Infect Dis</i>. 2017;65(12):e45-e80. doi:10.1093/cid/cix669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/29053792/pubmed" id="29053792" target="_blank">29053792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shih.2019">
<a name="Shih.2019"></a>Shih G, Wallace R. First-trimester pregnancy termination: uterine aspiration. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25299875">
<a name="25299875"></a>Shin B, Park HY, Koh WJ. Changes in QT intervals after azithromycin-containing antibiotic therapy in patients with NTM lung disease. <i>Int J Tuberc Lung Dis</i>. 2014;18(11):1385. doi:10.5588/ijtld.14.0306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25299875/pubmed" id="25299875" target="_blank">25299875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22965026">
<a name="22965026"></a>Shulman ST, Bisno AL, Clegg HW, et al; Infectious Diseases Society of America. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis.</i> 2014;58(10):1496]. <i>Clin Infect Dis.</i> 2012;55(10):e86-e102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22965026/pubmed" id="22965026" target="_blank">22965026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simon.1">
<a name="Simon.1"></a>Simon RH. Cystic fibrosis: overview of the treatment of lung disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26656010">
<a name="26656010"></a>Smith C, Egunsola O, Choonara I, Kotecha S, Jacqz-Aigrain E, Sammons H. Use and safety of azithromycin in neonates: a systematic review. <i>BMJ Open</i>. 2015;5(12):e008194. doi:10.1136/bmjopen-2015-008194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/26656010/pubmed" id="26656010" target="_blank">26656010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32303621">
<a name="32303621"></a>Smith D, Du Rand I, Addy CL, et al. British Thoracic Society (BTS) guideline for the use of long-term macrolides in adults with respiratory disease. <i>Thorax</i>. 2020;75(5):370-404. doi:10.1136/thoraxjnl-2019-213929<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/32303621/pubmed" id="32303621" target="_blank">32303621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32414479">
<a name="32414479"></a>Smith GN, Moore KM, Hatchette TF, Nicholson J, Bowie W, Langley JM. Committee Opinion No. 399: Management of tick bites and Lyme disease during pregnancy. <i>J Obstet Gynaecol Can</i>. 2020;42(5):644-653. doi:10.1016/j.jogc.2020.01.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/32414479/pubmed" id="32414479" target="_blank">32414479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spach.1">
<a name="Spach.1"></a>Spach DH. Bartonella infections in people with HIV. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spach.2">
<a name="Spach.2"></a>Spach DH, Kaplan SL. Treatment of cat scratch disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25297051">
<a name="25297051"></a>Sriratanaviriyakul N, Nguyen LP, Henderson MC, Albertson TE. Drug reaction with eosinophilia and systemic symptoms syndrome (DRESS) syndrome associated with azithromycin presenting like septic shock: a case report. <i>J Med Case Rep</i>. 2014;8:332. doi:10.1186/1752-1947-8-332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25297051/pubmed" id="25297051" target="_blank">25297051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7667049">
<a name="7667049"></a>Starke JR, Correa AG. Management of Mycobacterial Infection and Disease in Children. <i>Pediatr Infect Dis J</i>. 1995;14(6):455-469.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/7667049/pubmed" id="7667049" target="_blank">7667049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.<i> Clin Infect Dis.</i> 2014;59(2):147-159. doi:10.1093/cid/ciu296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26704020">
<a name="26704020"></a>Stokholm J, Chawes BL, Vissing NH, et al. Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years: a randomised, double-blind, placebo-controlled trial. <i>Lancet Respir Med</i>. 2016;4(1):19-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/26704020/pubmed" id="26704020" target="_blank">26704020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25595580">
<a name="25595580"></a>Sutton AL, Acosta EP, Larson KB, Kerstner-Wood CD, Tita AT, Biggio JR. Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis. <i>Am J Obstet Gynecol</i>. 2015;212(6):812.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/25595580/pubmed" id="25595580" target="_blank">25595580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23635050">
<a name="23635050"></a>Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. <i>N Engl J Med</i>. 2013;368(18):1704-1712. doi:10.1056/NEJMoa1300799<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/23635050/pubmed" id="23635050" target="_blank">23635050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21130389">
<a name="21130389"></a>Swamy N, Laurie SA, Ruiz-Huidobro E, Khan DA. Successful clarithromycin desensitization in a multiple macrolide-allergic patient. <i>Ann Allergy Asthma Immunol</i>. 2010;105(6):489-490. doi:10.1016/j.anai.2010.08.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/21130389/pubmed" id="21130389" target="_blank">21130389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15725048">
<a name="15725048"></a>Swanson RN, Lainez-Ventosilla A, De Salvo MC, Dunne MW, Amsden GW. Once-daily azithromycin for 3 days compared with clarithromycin for 10 days for acute exacerbation of chronic bronchitis: a multicenter, double-blind, randomized study. <i>Treat Respir Med</i>. 2005;4(1):31-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/15725048/pubmed" id="15725048" target="_blank">15725048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27620494">
<a name="27620494"></a>Thompson DF, Ramos CL. Antibiotic-induced rash in patients with infectious mononucleosis. <i>Ann Pharmacother</i>. 2017;51(2):154-162. doi:10.1177/1060028016669525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/27620494/pubmed" id="27620494" target="_blank">27620494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27682034">
<a name="27682034"></a>Tita AT, Szychowski JM, Boggess K, et al; C/SOAP Trial Consortium. Adjunctive azithromycin prophylaxis for cesarean delivery. <i>N Engl J Med</i>. 2016;375(13):1231-1241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/27682034/pubmed" id="27682034" target="_blank">27682034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16340941">
<a name="16340941"></a>Tiwari T, Murphy TV, Moran J; National Immunization Program, CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC guidelines. <i>MMWR Recomm Rep.</i> 2005;54(RR-14):1-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/16340941/pubmed" id="16340941" target="_blank">16340941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9517646">
<a name="9517646"></a>Trevisani L, Sartori S, Caselli M, Ruina M, Verdianelli G, Abbasciano V. A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection. <i>Am J Gastroenterol</i>. 1998;93(3):390-393.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/9517646/pubmed" id="9517646" target="_blank">9517646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17205438">
<a name="17205438"></a>Tribble DR, Sanders JW, Pang LW, et al. Traveler’s diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. <i>Clin Inf Dis</i>. 2007;44 (3):338-346.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/17205438/pubmed" id="17205438" target="_blank">17205438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8994766">
<a name="8994766"></a>Tseng AL, Dolovich L, Salit IE. Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus. <i>Clin Infect Dis</i>. 1997;24(1):76-77. doi:10.1093/clinids/24.1.76<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/8994766/pubmed" id="8994766" target="_blank">8994766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28923488">
<a name="28923488"></a>Ünal D, Demir S, Gelincik A, et al. Diagnostic value of oral challenge testing in the diagnosis of macrolide hypersensitivity. <i>J Allergy Clin Immunol Pract</i>. 2018;6(2):521-527. doi:10.1016/j.jaip.2017.06.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/28923488/pubmed" id="28923488" target="_blank">28923488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed April 29, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf</a>. Accessed February 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.4">
<a name="HHS.4"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new</a>. Updated June 14, 2023. Accessed June 27, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf.Updated December 9, 2019. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11535141">
<a name="11535141"></a>Uzun C, Koten M, Adali MK, Yorulmaz F, Yagiz R, Karasalihoglu AR. Reversible ototoxic effect of azithromycin and clarithromycin on transiently evoked otoacoustic emissions in guinea pigs. <i>J Laryngol Otol</i>. 2001;115(8):622-628. doi:10.1258/0022215011908676<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/11535141/pubmed" id="11535141" target="_blank">11535141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24746000">
<a name="24746000"></a>Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. <i>Lancet Respir Med</i>. 2014;2(5):361-368.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/24746000/pubmed" id="24746000" target="_blank">24746000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11574190">
<a name="11574190"></a>Van Bambeke F, Tulkens PM. Macrolides: pharmacokinetics and pharmacodynamics. <i>Int J Antimicrob Agents.</i> 2001;18(suppl 1):S17-S23. doi:10.1016/s0924-8579(01)00406-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/11574190/pubmed" id="11574190" target="_blank">11574190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22744719">
<a name="22744719"></a>van Ingen J, Egelund EF, Levin A, et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. <i>Am J Respir Crit Care Med</i>. 2012;186(6):559-565. doi:10.1164/rccm.201204-0682OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22744719/pubmed" id="22744719" target="_blank">22744719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216385">
<a name="27216385"></a>Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. <i>Int J Antimicrob Agents</i>. 2016;48(1):1-10. doi:10.1016/j.ijantimicag.2016.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/27216385/pubmed" id="27216385" target="_blank">27216385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32170033">
<a name="32170033"></a>Viscardi RM, Terrin ML, Magder LS, et al. Randomised trial of azithromycin to eradicate <i>Ureaplasma</i> in preterm infants. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2020;105(6):615-622. doi: 10.1136/archdischild-2019-318122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/32170033/pubmed" id="32170033" target="_blank">32170033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33658655">
<a name="33658655"></a>Viscardi RM, Terrin ML, Magder LS, et al. Randomized trial of azithromycin to eradicate <i>Ureaplasma</i> respiratory colonization in preterm infants: 2-year outcomes. <i>Pediatr Res</i>. 2022;91(1):178-187. doi:10.1038/s41390-021-01437-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/33658655/pubmed" id="33658655" target="_blank">33658655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20619683">
<a name="20619683"></a>Vos R, Vanaudenaerde BM, Ottevaere A, et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? <i>J Heart Lung Transplant</i>. 2010;29(12):1358-1368.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/20619683/pubmed" id="20619683" target="_blank">20619683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7854392">
<a name="7854392"></a>Wahlstrom E, Zamora JU, Teichman S. Improvement in cyclosporin-associated gingival hyperplasia with azithromycin therapy. <i>N Engl J Med.</i> 1995;332(11):753-754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/7854392/pubmed" id="7854392" target="_blank">7854392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23796742">
<a name="23796742"></a>Wald ER, Applegate KE, Bordley C, et al. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. <i>Pediatrics</i>. 2013;132(1):e262-e280.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/23796742/pubmed" id="23796742" target="_blank">23796742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7904701">
<a name="7904701"></a>Wallace MR, Miller LK, Nguyen MT, Shields AR. Ototoxicity with azithromycin. <i>Lancet</i>. 1994;343(8891):241. doi:10.1016/s0140-6736(94)91030-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/7904701/pubmed" id="7904701" target="_blank">7904701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al. Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update. <i>Perit Dial Int</i>. 2012;32(suppl 2):S32-S86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29272341">
<a name="29272341"></a>Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset <i>Clostridium difficile</i> infections in a large healthcare system. <i>Clin Infect Dis</i>. 2018;66(12):1957-1959. doi:10.1093/cid/cix1112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/29272341/pubmed" id="29272341" target="_blank">29272341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28889106">
<a name="28889106"></a>Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>Eur Respir J</i>. 2017;50(3):1602265. doi:10.1183/13993003.02265-2016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/28889106/pubmed" id="28889106" target="_blank">28889106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30125557">
<a name="30125557"></a>White KO, Jones HE, Lavelanet A, et al. First-trimester aspiration abortion practices: a survey of United States abortion providers. <i>Contraception</i>. 2019;99(1):10-15. doi:10.1016/j.contraception.2018.08.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/30125557/pubmed" id="30125557" target="_blank">30125557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29665357">
<a name="29665357"></a>White KO, Jones HE, Shorter J, et al. Second-trimester surgical abortion practices in the United States. <i>Contraception</i>. Published online April 14, 2018. doi:10.1016/j.contraception.2018.04.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/29665357/pubmed" id="29665357" target="_blank">29665357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wiesenfeld.1">
<a name="Wiesenfeld.1"></a>Wiesenfeld HC. Pelvic inflammatory disease: treatment in adults and adolescents. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 27, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29790845">
<a name="29790845"></a>Williams PCM, Berkley JA. Guidelines for the treatment of dysentery (shigellosis): a systematic review of the evidence. <i>Paediatr Int Child Health</i>. 2018;38(sup1):S50-S65. doi:10.1080/20469047.2017.1409454<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/29790845/pubmed" id="29790845" target="_blank">29790845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22901872">
<a name="22901872"></a>Wilson R, Wells AU. Azithromycin in bronchiectasis: when should it be used? <i>Lancet</i>. 2012;380(9842):627-629.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22901872/pubmed" id="22901872" target="_blank">22901872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17446442">
<a name="17446442"></a>Wilson W, Taubert KA, Gewitz M, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. <i>Circulation.</i> 2007;116(15):1736-1754. doi:10.1161/CIRCULATIONAHA.106.183095<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/17446442/pubmed" id="17446442" target="_blank">17446442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33853363">
<a name="33853363"></a>Wilson WR, Gewitz M, Lockhart PB, et al; American Heart Association Young Hearts Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and the Council on Quality of Care and Outcomes Research. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. <i>Circulation</i>. 2021;143(20):e963-e978. doi:10.1161/CIR.0000000000000969<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/33853363/pubmed" id="33853363" target="_blank">33853363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11867823">
<a name="11867823"></a>Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. <i>Thorax</i>. 2002;57(3):212-216.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/11867823/pubmed" id="11867823" target="_blank">11867823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22901887">
<a name="22901887"></a>Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomized, double-blind, placebo-controlled trial. <i>Lancet.</i> 2012;380(9842):660-667.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/22901887/pubmed" id="22901887" target="_blank">22901887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30734107">
<a name="30734107"></a>Woodhead JL, Yang K, Oldach D, et al. Analyzing the mechanisms behind macrolide antibiotic-induced liver injury using quantitative systems toxicology modeling. <i>Pharm Res</i>. 2019;36(3):48. doi:10.1007/s11095-019-2582-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/30734107/pubmed" id="30734107" target="_blank">30734107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26598102">
<a name="26598102"></a>Woodruff AE, Meaney CJ, Hansen EA, Prescott GM. Azithromycin-induced, biopsy-proven acute interstitial nephritis in an adult successfully treated with low-dose corticosteroids. <i>Pharmacotherapy</i>. 2015;35(11):e169-e174. doi:10.1002/phar.1660<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/26598102/pubmed" id="26598102" target="_blank">26598102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al; Centers for Disease Control and Prevention (CDC). Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. https://apps.who.int/iris/handle/10665/62435. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Guidelines for the control of shigellosis, including epidemics due to <i>Shigella dysenteriae</i> type 1. http://apps.who.int/iris/bitstream/10665/43252/1/924159330X.pdf?ua=1. Published 2005. Accessed July 23, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.3">
<a name="WHO.3"></a>World Health Organization (WHO). Guidelines for the Treatment of<i> Chlamydia trachomatis.</i> Geneva, Switzerland: World Health Organization; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27512795">
<a name="27512795"></a>World Health Organization (WHO). Guidelines for the Treatment of<i> Neisseria gonorrhoeae.</i> Geneva, Switzerland: World Health Organization; 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/27512795/pubmed" id="27512795" target="_blank">27512795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17029130">
<a name="17029130"></a>Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis. </i>2007;45(7):941]. <i>Clin Infect Dis.</i> 2006;43(9):1089-1134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/17029130/pubmed" id="17029130" target="_blank">17029130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20047477">
<a name="20047477"></a>Wormser GP, Prasad A, Neuhaus E, et al. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection. <i>Clin Infect Dis</i>. 2010;50(3):381-386. doi:10.1086/649859<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/20047477/pubmed" id="20047477" target="_blank">20047477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29505509">
<a name="29505509"></a>Xu L, Zhu Y, Yu J, Deng M, Zhu X. Nursing care of a boy seriously infected with Steven-Johnson syndrome after treatment with azithromycin: A case report and literature review. <i>Medicine (Baltimore)</i>. 2018;97(1):e9112. doi:10.1097/MD.0000000000009112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/29505509/pubmed" id="29505509" target="_blank">29505509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28408648">
<a name="28408648"></a>Yang Z, Prinsen JK, Bersell KR, et al. Azithromycin causes a novel proarrhythmic syndrome. <i>Circ Arrhythm Electrophysiol</i>. 2017;10(4):e003560. doi:10.1161/CIRCEP.115.003560<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/28408648/pubmed" id="28408648" target="_blank">28408648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26897386">
<a name="26897386"></a>Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. <i>J Am Acad Dermatol</i>. 2016;74(5):945-973.e33. doi:10.1016/j.jaad.2015.12.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/26897386/pubmed" id="26897386" target="_blank">26897386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32585019">
<a name="32585019"></a>Zaroff JG, Cheetham TC, Palmetto N, et al. Association of azithromycin use with cardiovascular mortality. <i>JAMA Netw Open</i>. 2020;3(6):e208199. doi:10.1001/jamanetworkopen.2020.8199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/azithromycin-systemic-pediatric-drug-information/abstract-text/32585019/pubmed" id="32585019" target="_blank">32585019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.1">
<a name="Pfizer.1"></a>Zithromax (azithromycin) injection [prescribing information]. New York, NY: Pfizer Labs; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.2">
<a name="Pfizer.2"></a>Zithromax (azithromycin) 250 mg and 500 mg tablets and oral suspension [prescribing information]. New York, NY: Pfizer Labs; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.3">
<a name="Pfizer.3"></a>Zithromax (azithromycin) 600 mg tablets and oral suspension [prescribing information]. New York, NY: Pfizer Labs; November 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.4">
<a name="Pfizer.4"></a>Zithromax (azithromycin) tablet [prescribing information]. New York, NY: Pfizer Labs; April 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 15943 Version 767.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
